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 It is widely accepted that the emergence of drug-resistant pathogens is the result 
of the overuse and misuse of antibiotics. Infectious Disease Society of America, Center 
for Disease Control and World Health Organization continue to view, with concern, the 
lack of antibiotics in development, especially those against Gram-negative bacteria.  
 Antimicrobial peptides (AMPs) have been proposed as an alternative to 
antibiotics due to their selective activity against microbes and minor ability to induce 
resistance. For example, the Food and Drug Administration approved Daptomycin (DAP) 
in 2003 for treatment of severe skin infections caused by susceptible Gram-positive 
organisms.  Currently, there are 12 to 15 examples of modified natural and synthetic 
AMPs in clinical development. But most of these agents are against Gram-positive 
bacteria. Therefore, there is unmet medical need for antimicrobials used to treat 
infections caused by Gram-negative bacteria. 
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 In this study, we show that a pro-apoptotic peptide predominantly used in cancer 
therapy, (KLAKLAK)2, is an effective antimicrobial against Gram-negative laboratory 
strains and clinical isolates. Despite the therapeutic promise, AMPs development is 
hindered by their susceptibility to proteolysis. Here, we demonstrate that an all-D 
enantiomer of (KLAKLAK)2, resistant to proteolysis,  retains its activity against Gram-
negative pathogens. In addition, we have elucidated the specific site and mechanism of 
action of D(KLAKLAK)2 through a repertoire of whole-cell and membrane-model assays. 
 Although it is considered that development of resistance does not represent an 
obstacle for AMPs clinical development, strains with decreased susceptibility to these 
compounds have been reported. Staphylococci resistance to DAP was observed soon after 
its approval for use and has been linked to alterations of the cell wall (CW) and cellular 
membrane (CM) properties. Immediately following staphylococcal resistance, 
Enterococci resistance to DAP was seen, yet the mechanism of resistance in enterococci 
remains unknown. Our findings demonstrate that, similar to S. aureus, development of 
DAP-resistance in a vancomycin-resistant E. faecalis isolate is associated with alterations 
of the CW and properties of the CM. However, the genes linked to these changes in 
enterococci appear to be different from those described in S. aureus.  
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Chapter I 
Introduction 
 
Antimicrobial Resistance 
  
 Resistance to single antibiotics is not a new phenomenon.  Although, the 
first antibiotic -- penicillin-- was discovered in 1928, large-scale production did not start 
until 1940. By 1944, staphylococci had become resistant to penicillin (1). Partially, this 
phenotype was due to the secretion of a specific enzyme, penicillinase, able to degrade 
penicillin (2, 3).  Ever since, the introduction of new classes of antibiotics increased the 
selective pressure on specific microbial populations resulting in the emergence of multi-
drug-resistant (MDR) organisms. These microbes are resistant to many classes of 
antibiotics due to several different types of resistance mechanisms including: enzymatic 
mechanisms of drug modification, enhanced efflux pump expression, altered membrane 
permeability, and mutated drug targets. 
                         
Genetics of antibiotic resistance 
 Bacteria can become resistant to antibiotics through intrinsic or acquired 
mechanisms.  The mechanisms of acquired resistance involve chromosomal mutations, 
horizontal gene transfer of resistance determinants (4) or a combination of these two 
means.    
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Spontaneous mutations  
 Spontaneous mutations occur randomly in the form of incorrect repair of DNA 
damage or replication errors in actively dividing cells (5).  Point mutations confer 
resistance when they are able to produce a resistance phenotype, and allow growth of the 
bacteria despite the presence of antibiotics (2, 6). Mutations leading to resistance usually 
map to the target of antibiotics. For example, mutations in the genes encoding RpoB and 
topoisomerases, which are the targets of rifampicins and fluorquinolones, confer 
resistance to these molecules (7, 8).  In addition, mutations in the promoter regions of 
regulatory genes (9, 10) encoding for efflux or uptake systems also lead to resistance. In 
the case of P. aeruginosa, reduced expression of the OprD porin leads to resistance to 
carbapenems (11).  Mutations that lead to the up-regulation of antibiotic-inactivating-
enzymes also increase antimicrobial resistance. 
 
Hypermutator phenotype 
 Normally, spontaneous mutation rates due to errors produced in the DNA 
replication process in a species remain low due to the activity of molecular mechanisms 
that act to repair and protect DNA. However, bacteria with high mutation rates have 
been identified.  The majority of the bacteria with high mutation rates (hypermutators) 
have an inactive mutS or mutL gene, which leads to a defective mismatch repair (MMR) 
system (12).  Usually, MMR eliminates biosynthetic errors and prevents recombination 
by non-identical DNA sequences (13).  Hypermutable phenotypes act by accelerating the 
emergence mutations responsible for antibiotic resistance (7, 14, 15).   
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Adaptive mutagenesis 
 In addition to mutations that occur due to errors during the DNA replication 
process, mutations can also occur in non- or slowly dividing cells. These mutations, 
called adaptive mutations, differ from spontaneous mutations based on their occurrence 
only in the presence of non-lethal selective pressure that favors them (4), such as a sub-
inhibitory drug concentration which often arises when treatment doses of antibiotics are 
not followed.   
 
Horizontal gene transfer (HGT) 
 The first evidence of HGT was the recognition of the transfer of virulence 
determinants between pneumococci in infected mice (16).  HGT can be the result of one 
of three mechanisms: (i) natural transformation (Figure 1-1) defined by stable uptake, 
integration and expression of extracellular DNA; (ii) transduction mediated by 
bacteriophages or (iii) conjugative transfer (Figure 1-2), where a cell-to-cell junction or 
pillus mediates transfer.   
 Natural transformation occurs when competent bacteria uptake free extracellular 
DNA molecules present in the environment. Extracellular DNA is released from 
disrupted or decomposing cells, bacteriophage, or naturally excreted from living cells 
(17). Competence is most often a time-limited physiological state involving up to 50 
proteins (17). It is usually regulated in response to specific environmental conditions, 
although some, most importantly pathogenic bacteria, are naturally competent. The 
conditions that lead to bacterial cell competence are often altered growth conditions, cell  
  5 
Figure 1-1. Natural Transformation
“The steps involved in this process include the release of extracellular 
DNA into the environment and the uptake of DNA into the cytoplasm of 
the recipient bacterial cell that has developed a regulated physiological 
state of competence. Following uptake, for the transferred DNA to persist 
it must integrate into the bacterial genome through homologous 
recombination or by sequence-independent, illegitimate recombination. 
Plasmids that succeed in reconstituting a replication-proficient form do 
not need to integrate into the host genome.”
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews 
Microbiology (Allen et al, 2010) copyright (2010). 
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“In the donor, the events depicted are: a, integration of the plasmid into the 
chromosome by recombination between insertion sequence elements; b, 
movement of a transposable element through a circular intermediate from the 
chromosome to the plasmids; c, initiation of rolling-circle replication at the
mating-pair apparatus. In the recipient cell, the events depicted are: d, 
recircularization; e, attack by restriction endonucleases (scissors); f, 
replication; g, integration into the chromosome by an illegitimate Campbell
recombination; h, recombination between transferred chromosomal DNA and 
the resident chromosome.”
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews 
Microbiology (Allen et al, 2010) copyright (2010).  
Figure 1-2.  Conjugative transfer.
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density, starvation or nutrient access. Competence in the bacterial population can range 
anywhere from 0 to 100%. Transformation begins with non-covalent binding of DNA to 
the cell surface, followed by translocation across the inner membrane. With the 
exception of plasmids, DNA must integrate into the bacterial genome to persist.   
 The transfer of DNA from donor bacteria to recipient bacteria is mediated by 
infection with a bacteriophage is called transduction.  There are 2 types of transduction: 
generalized and specialized. Generalized transduction occurs when an individual lytic 
phage carrying different sets of genes pertaining to the bacterial genome transfers the 
foreign DNA to another bacterium (18). Specialized transduction occurs when individual 
phage transfer the same genetic information, usually present adjacent to the insertion 
site.  A lysogenic phage inadvertently becomes lytic and improperly expels itself from 
the genome caring the flanking host DNA sequences. Upon infection, the extraneous 
DNA is transferred to another bacterium. (18).   
 Conjugation occurs when all or part of the donor plasmid is transferred through 
direct contact between donor and recipient bacteria (Figure 1-1).  The ability of the 
donor bacteria to transfer its genetic material is determined by specific conjugative 
plasmids; where strains of bacteria with the plasmid function as donors and those that 
lack the plasmid function as recipients (18).    
  
Modes of antibiotic resistance 
 Antibiotic resistance emerges by one of 4 mechanisms: (i) direct inactivation of 
the antibiotic molecule (19), (ii) alteration of the target of the antibiotic (20), (iii) 
reducing the concentration of the drug without modifying the drug itself, through efflux 
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pumps and outer membrane permeability (21), iv) bypassing the inactivation of a given 
enzyme or cellular process (22). 
 
Antibiotic inactivation 
 Antibiotics can be inactivated by the production of enzymes that degrade or 
modify the antibiotic molecule through hydrolysis, group transfer or redox mechanisms 
(4).  A classical example of inactivation by hydrolysis are the chromosomally and 
plasmid-encoded β-lactamase enzymes that cleave the β-lactam ring of penicillin and 
cephalosporin antibiotics.  In addition to the over 200 β-lactamases identified to date (4), 
over 180 extended-spectrum β-lactamases have been discovered that confer resistance to 
all penicillins, third generation cephalosporins and aztreonam (4).  Esterases and 
epoxidases confer resistance to macrolides and fosomycin, respectively (23, 24, 25). 
Transferases inactivate antibiotics by chemical substitution, leading to altered binding to 
the antibiotic target.  Oxidation and reduction of antibiotics has been infrequently 
identified in pathogenic bacteria (26).  
 
Target modification 
 Modification of the target comes in the form of peptidoglycan structure 
alteration, protein synthesis interference and DNA synthesis interference, which leads to 
the inability of the antibiotic to bind. Peptidoglycan is an essential component of the 
bacterial cell-wall (CW), and therefore the enzymes involved in its synthesis and 
assembly serve as excellent targets for antibiotics.  Often, penicillin-binding proteins are 
mutated; these mutations lead to decreased affinity of β-lactam antibiotics (27, 28, 29).  
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In addition to penicillin binding proteins, often bacteria will acquire mutations causing 
alterations of the C-terminal site of peptidoglycan pre-cursors, which are common 
targets of glycopeptides.   
 Mutations in the bacterial 50S ribosomal subunit are a common form of 
resistance to many antibiotics whose mechanism of action is interfering with protein 
metabolism.  For example, a post-transcriptional modification to the 23S rRNA in the 
50S ribosomal subunit confers resistance to macrolides, lincosamides and streptogramin 
B (30).  In addition to the 23S subunit, mutations in the 16S rRNA gene are also 
common and confer resistance to aminoglycosides.   
 Topoisomerase IV and DNA gyrase contain sites of interaction for 
fluoroquinolones. This interaction causes a cessation of DNA replication and 
transcription.  Fluoroquinolone resistance is often the result of mutations in the structural 
genes encoding for these molecules, leading to the inability of antibiotics to bind (31). 
 
Outer membrane permeability and efflux pumps 
 Decreased outer membrane permeability results in reduced antibiotic uptake. 
When coupled with efflux pumps increased activity, the concentration of antibiotic is 
kept at very low levels inside the cell.  Efflux pumps affect all classes of antibiotics and 
vary widely in their specificity and mechanism (32, 33).  Some pumps are very drug 
specific, while others are multi-drug transporters and efflux a wide variety of unrelated 
antibiotics (34).   
 Antibiotics must cross the outer membrane of Gram-negative bacteria to reach 
their cellular target. This process is accomplished by either diffusion or self-promoted 
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uptake (4).  Diffusion takes place through porins or directly through the bilayer. 
Mutations in porins such as number, size and selectivity will greatly alter the rate of 
diffusion of antibiotics (35, 36, 37, 38, 39).   
 
Pseudomonas aeruginosa 
 
Microbiology 
 Pseudomonas aeruginosa is a non-fermentive, motile Gram-negative rod that is 
ubiquitous in soil and water (40, 41).  In nature, P. aeruginosa is found in many forms 
such as a biofilm, attached to a surface or substrate, or in a planktonic form, as a 
unicellular organism. It is tolerant to a wide variety of physical conditions, including 
temperature, and is resistant to high concentrations of salts, dyes, weak antiseptics, and 
many commonly used antibiotics.  
 
Disease 
 P. aeruginosa is recognized as a major cause of nosocomial bacteremia and 
infections associated with invasive devices, mechanical ventilation, burn wounds, or 
surgeries (42).  The worldwide emergence of MDR nosocomial clones has added 
significantly to the ominous prognosis of P. aeruginosa infections.  
 
Pathogenesis 
 P. aeruginosa has a wide host of virulence factors and produces many toxins and 
surface components associated with virulence (43, 44, 45). P. aeruginosa undertake two 
  11 
main mechanisms of pathogenic behavior: i) remains confined as a chronic infection, for 
example, in the lungs of cystic fibrosis (CF) patients or ii) invades tissues causing 
bacteremia and pneumonia, usually resulting in septic shock and death.   
 In the CF chronic lung infection, P. aeruginosa usually down-regulates its toxins 
(46), loses its ‘O’ side chains (47), loses its flagellum and pilli (48, 49) and  expresses 
alginate (mucoid coat) on the surface to protect itself from phagocytosis (50). Although 
the flagellum of P. aeruginosa are down regulated in chronic infections, it plays an 
important role in dispersal and adhesion to host cells (51, 52, 53, 54).  These mutations 
are important to the persistence of P. aeruginosa because production of these factors 
would elicit an immune response, and without them the organism is able to evade the 
immune mechanisms in the lungs.  
 P. aeruginosa employs a secretion system composed of 43 genes called the type 
III secretion system (TTSS), to inject specific  toxins directly into the host cell (55), 
(56).  Four effector proteins have been identified: ExoS, ExoT, ExoU and ExoY of 
which ExoS, ExoT and ExoU have been related to virulence (57).  ExoS and ExoT are 
found in 70 to 100% of clinical isolates, respectively (58) and contribute to phagocytosis 
inhibition. Their mechanism of action involves disruption of host cell actin cytoskeleton 
resulting in cell death (59).  The ExoU gene is found in only 30% of clinical isolates (59) 
and encodes for phospholipase A2 (PLA2) (60, 61).  The PLA2 activity of ExoU leads to 
dissolution of the plasma cell membrane, followed by rapid cell death (60, 61, 62) and a 
large increase in production of prostaglandins (63) leading to increased tissue damage 
and excessive inflammation.   
 Quorum sensing (QS) is another important virulence mechanism of P. 
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aeruginosa.  When bacteria reach high density, they secrete a QS effector molecule 
called autoinducer, which is sensed by neighboring bacteria (64). In P. aeruginosa, the 
QS system regulates many processes from production of toxins to biofilm formation (65, 
66, 67, 68, 69, 70, 71).  
 
Mechanisms of Antibiotic Resistance 
 P. aeruginosa is one of the leading causes of nosocomial infections worldwide 
(72).  Besides intrinsic resistance determinants, P. aeruginosa has the ability to acquire 
further resistance mechanisms making infection with this pathogen often hard to treat.  
Almost all known mechanisms of antimicrobial resistance have been demonstrated in P. 
aeruginosa.  Often these resistance mechanisms are not present singularly but in concert 
with each other, thereby conferring a multi-resistant phenotype.   
 The most prevalent mechanism of resistance to β-lactams is enzyme production.  
In 1980, Ambler (73) described the molecular classification of β-lactamases based on the 
nucleotide and amino acid sequences of the enzymes.  There are 4 recognized classes 
named A-D, correlating with their functional classification (74).  Classes A, C and D act 
through a serine based mechanism, class B are known as the metallo-β-lactamases 
(MBLs) and require zinc for their action. P. aeruginosa expresses significant numbers of 
enzymes pertaining to all classes (A-D). 
 AmpC β-lactamase is an inducible chromosomally encoded molecular class C 
enzyme that is usually produced in low quantities by P. aeruginosa (75).  However, in 
the presence of inducing β-lactams its production increases 100-1000 times (76). Four 
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carbenicillin hydrolyzing β-lactamases belong to molecular class A (77).  To date, P. 
aeruginosa has not been found to have plasmid mediated cephalosporinases.  
 PER-1 was the first fully characterized extended spectrum β-lactamase (ESBL).  
It was found to be chromosomally encoded but has since been reported to be plasmid 
mediated (78).   
 In addition to class A ESBLs, many class D β-lactamases, also known as 
oxacillinases (OXA), have been identified in P. aeruginosa.  The classical OXA enzyme 
can confer resistance to carboxypenicillins and ureidopenicillins but not to ceftazidime 
(77). However, the OXA types identified in P.aeruginosa, are able to hydrolyze 
ceftaxidime, and therefore have great clinical importance.  Moreover, this type of OXA 
is also able to hydrolyze many other antibiotics.  Their spectrum includes: cefotaxime, 
cefepime, cefepime aztreonam, and moxalactam.  In addition to a wide spectrum of 
effectiveness, these OXA types are at most instances not suppressed by β-lactamase 
inhibitors (79). 
 P.aeruginosa can also produce carbapenem-hydrolyzing enzymes that belong to 
the molecular class B (74), known as carbapenemase or MBLs (78). Production of 
carbapenemases confers resistance to all β-lactams, except the monobactam and 
aztreonam.   
 The high molecular mass proteins OprM, OprJ, OprN present in the outer 
membrane of P. aeruginosa contribute to low membrane permeability (80) and act as 
components of active efflux systems with wide substrate specificity (81).  Efflux also 
contributes to the development of a multi-resistant phenotype and is mediated by four 
genetically different three-component efflux systems: (81, 82) MexA–MexB–OprM, 
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MexC–MexD–OprJ, MexE–MexF–OprN, and MexX–MexY–OprM.  These three 
component systems have similar structures with the first component operating as an 
energy dependant pump located in the cytoplasmic membrane (MexB, MexD, MexF and 
MexY). The second component functions as an outer membrane protein (OprM, OprJ, 
OprN and OprM). The third protein functions as a linker between the other two proteins 
and is located in the periplasmic space (MexA, MexC, MexE and MexX) (82).   
 OprD is a protein that forms specific channels that allow the entry of basic amino 
acids and carbapenems into the cell (81).  A deficiency of the OprD porins is observed in 
imipenem-resistant P. aeruginosa isolates (83).  Rarely, it has been observed that P. 
aeruginosa can alter its penicillin binding proteins, the active site for β-lactam 
antibiotics (83). 
 Resistance to aminoglycosides comes in the form of enzyme modification, and to 
a lesser extent, decreased outer membrane permeability, target modification and active 
efflux (84, 85, 86).  There are 3 classes of aminoglycoside modifying enzymes (AMEs); 
aminoglycoside phosphotransferase (APHs), aminoglycoside adenylyltransferases 
(AADs) and aminoglycoside acetyltransferases (AACs).  AMEs function by decreasing 
the binding affinity of the aminoglycoside to the bacterial 30S ribosomal subunit by 
attaching a phosphate, adenyl or acetyl radical to the aminoglycoside molecule (87).   
Although active efflux and target modification (88) are less common, they do remain 
important in conferring resistance of P. aeruginosa to aminoglycosides.  
 Resistance to fluoroquinolones is the result of structural changes in DNA gyrase 
and active efflux (89).  Mutated DNA gyrase has a low binding affinity for the quinolone 
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molecules.  Fluoroquinolones are also universal substrates for most all efflux systems 
present in P. aeruginosa. 
 
Acinetobacter 
 
Microbiology 
 The Acinetobacter genus comprises Gram-negative, non-fermenting, non-motile, 
catalase-positive, oxidase-negative, strictly aerobic bacteria. Acinetobacter species are 
considered ubiquitous organisms (90, 91).  A.baumannii is the most important 
nosocomial Acinetobacter species. It has a low carrier rate and is found rarely (0.5%-
3%) on human skin (92, 93).  
 
Disease 
 In a large surveillance study in the United States, it was found that between 5-
10% of cases of ICU-acquired pneumonia were due to A. baumannii (94).  In addition to 
being identified as the causative agent in hospital-acquired pneumonia, A. baumannii has 
also been implicated in community-acquired pneumonia, described in tropical regions of 
Australia and Asia (95, 96, 97, 98, 99).  Diagnosis of community acquired A. baumannii 
pneumonia occurs most commonly in people with a history of alcohol abuse and some 
admission to the ICU (95) and is characterized by secondary bloodstream infection and a 
mortality rate of 40-60% (99).  In addition to pneumonia, A. baumannii can also cause 
serious bloodstream infections. In a US study of blood stream infections from 1995-
2002, A. baumannii was the 10th most common etiologic agent (100). Sources of A. 
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baumannii blood stream infections are typically line related or attributed to underlying 
pneumonia, urinary tract (UTI) or wound infection (101).  In patients with nosocomial 
postsurgical meningitis, A. baumannii mortality is as high as 70% (102).  Endocarditis 
caused by Acinetobacter is not very common (103, 104, 105, 106) and usually involves 
prosthetic valves.  In addition, Acinetobacter-caused dophthalmitis or keratitis have 
been reported in relation to contact lens usage or eye surgery (107, 108).   
 
Pathogenesis 
 Although there are no known diffusible toxins or cytolysins associated with A. 
baumannii, genes have been identified that are involved in pillus biogenesis, iron uptake 
and metabolism, QS and the type IV secretion system (109, 110).  A.baumannii is able to 
form biofilms, which contributes to drug resistance and evasion of the host immune 
system (111, 112).  A.baumannii also often display pilli or fimbriae which are important 
for adhesion leading to eukaryotic cell invasion and promotion of apoptosis of the 
eukaryotic cell (113).   
 
Mechanisms of Antibiotic Resistance 
 In addition to innate resistance mechanisms, A. baumannii has acquired many 
foreign resistance determinants which has lead to a broad resistance profile.  The most 
prevalent resistance mechanism to β-lactam antibiotics is enzymatic degradation.  All A. 
baumannii have chromosomally encoded AmpC cephalosporinases (114, 115, 116, 117).  
In many Gram-negatives this is inducible, however, in A. baumannii the over expression 
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of AmpC is controlled by an upstream IS element known as ISAba1 (118, 119, 120, 121, 
117).  
 To resist the effects of carbapenems, A. baumannii produces β-lactamases with 
carbapenemase activity and serine oxacillinases known as Ambler class D OXA type.  
The enzymes encoded are class D meaning that the products have a higher affinity for 
imipenem than for meropenem (122, 123).  
 A.baumannii also expresses MBLs, an Ambler class B-type enzyme (124, 125).  
MBLs are less commonly identified in A. baumannii but are 100-1000 fold more potent 
then OXA (124).  MBLs have hydrolytic activity toward all β-lactams except 
monobactam and aztreonam.  There are 5 currently described MBL groups in the 
literature (126) with only 3 of these currently identified in A. baumannii.   
 In addition to enzymatic mechanism of resistance to β-lactams, A. baumannii can 
possess many non-enzymatic resistance mechanisms including changes to the outer 
membrane protein (114, 127, 128, 129), multi-drug efflux pumps (120, 130, 131)  and 
alteration in the affinity or expression of penicillin-binding proteins (132, 133, 134).   
 Genes coding for all classes (acetyltransferases, nucleotidyltransferases, and 
phosphotransferases) of AMEs have been identified in A. baumannii (135, 115).  In 
addition, a plasmid borne gene, armA, impairs the ability of aminoglycosides to bind to 
16s rRNA through methylation.   Resistance to quinolones appears in the form of 
described mutations in the gyrA and parC genes which lead to modifications to DNA 
gyrase or topoisomerase IV and cause interference with target binding (136, 137).  
Quinolones are substrates for AdeABC (130, 131) and the MATE pump, AdeM (138).  
Resistance to tetracyclines and glycylcyclines in A. baumannii is the result of efflux 
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through tet-a and tet-b (139, 140, 141) and the AdeABC pump (131).  In addition, A. 
baumannii can employ ribosomal protection to resist the effects of tetracyclines 
mediated by tet(M) and tet(O) determinants.  Recent reports have demonstrated in vitro 
resistance of A. baumannii to polymyxins, but the mechanism remains unknown (141, 
142).  Trimethoprim and sulfamethoxazole resistance in A. baumannii is becoming 
prevalent in many areas (143).  Recently, genes encoding for resistance to trimethoprim 
(dhfr) and resistance to chloramphenicol (cat) have been reported (144). 
 
Escherichia coli 
 
Microbiology 
 E. coli is a rod-shaped, Gram-negative, non-sporulating facultative anaerobe that 
grows on a variety of substrates, and is a member of the normal flora in mammals (145).  
Its optimal growth occurs at 37°C, but some laboratory strains can grow in temperatures 
up to 49°C (146).   
 
Disease 
 Normally, E. coli doesn’t cause disease and co-exists with its host for a lifetime, 
however, there are 3 general clinical syndromes that can result from infection with a 
virulent E. coli: sepsis/meningitis, enteric/diarrheal disease, and urinary tract infections 
(UTIs) (145). 
 
 
  19 
 
Pathotypes and pathogenesis   
 
Enteropathogenic E. coli (EPEC) 
 EPEC was the first pathotype of E. coli to be described. Currently, EPEC is an 
important cause of fatal infant diarrhea in developing countries (147).  The TTSS is 
activated in EPEC following binding to epithelial cells.  Following activation, effector 
proteins including Tir, and numerous other molecules are translocated into the host cell. 
EPEC will then bind to the host cell through an interaction of intimin with Tir.  
Following this interaction there is activation of protein kinase C (PKC), myosin light-
chain kinase, phospholipase Cγ and mitogen-activated protein (MAP) kinases which lead 
to nuclear factor kappa B (NF-kB) activation and IL-8 production (147, 148, 149).  
Diarrhea due to EPEC results from multiple mechanisms including inflammation, ion 
secretion and increased intestinal permeability (145).  
 
Enterohaemorrhagic E. coli (EHEC) 
 EHEC is infective at a very low dose (<100 cells) and causes bloody and non-
bloody diarrhea and hemolytic uremic syndrome (HUS) (145).  The main virulence 
factor of EHEC is Stx or verocytotoxin (VT), which in addition to local damage to the 
colon, damages the renal endothelial cells of the kidneys. Stx is produced in the colon 
and travels in the bloodstream to the kidneys where it binds to the target cell surface and 
cleaves ribosomal RNA leading to loss in protein synthesis (150).  This leads to renal 
inflammation (151) through cytokine and chemokine production and this damage leads 
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to HUS.  Besides Stx, most EHEC strains have a type III secretion system and other 
effector proteins present in EPEC.   
 
Enterotoxigenic E. coli (ETEC) 
 ETEC is the main cause of diarrhea in travelers in developing countries and is an 
important cause of childhood diarrhea in the developing world (147).  ETEC attaches to 
and colonizes the surface of the mucosa of the small bowel and secretes heat-labile (LT) 
and heat-stable (STs) enterotoxin. LT causes a permanent activation of adenylate cyclase 
through its ADP-ribosyl transferase activity leading to increased levels of intracellular 
cAMP.  The increased levels of cAMP induce activation of cAMP-dependant kinases 
and eventual activation of the CF trans-membrane conductance regulator (CTFR).  
CTFR is the main chloride (Cl-) channel in epithelial cells and the result of its 
phosphorlyation is increased Cl- secretion and diarrhea (152).  LT also causes an 
increase in secretion of water and mucous as well as an inhibition of absorption through 
stimulation of prostaglandin synthesis and the enteric nervous system (152).   
 STs have two sub-classes: STa and STb, of which only the STa class has been 
associated with disease in humans (147).  When STa binds to its guanylate cyclase 
receptor it stimulates its activity leading to increased intracellular cGMP.  The increased 
intracellular cGMP activates kinases, which increase secretion of water and mucous. 
 
Enteroaggregative E. coli (EAEC) 
 EAEC is the cause of persistent diarrhea in both children and adults and is 
characterized by its autoaggregative adherence pattern in which bacteria adhere to each 
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other in a ‘stacked brick’ pattern (147).  EAEC colonizes the intestinal mucosa of the 
colon causing secretion of enterotoxins and cytotoxins (153) and induces significant 
mucosal damage (154).  There are several toxins and virulence factors attributed to 
EAEC. Although no single factor has been directly proven, epidemiological studies have 
implicated similar virulence factors of other enteric pathogens (155, 156). 
 
Enteroinvasive E. coli (EIEC) 
EIEC pathogenesis is characterized by dissemination into epithelial cells by cell 
penetration, lysis of the endocytic vacuole and intracellular multiplication followed by 
movement through the cytoplasm and extension into adjacent epithelial cells (145).  It 
has been shown that EIEC can induce apoptosis in infected macrophages (157).  In 
addition to the type III secretion system that is essential for the invasiveness of EIEC 
(158), additional virulence factors such as the serine protease Sep A and the aerobactin 
iron-acquisition system have been described.   
 
Diffusely adherent E. coli (DAEC) 
 DAEC are the cause of diarrhea in children older than 12 months of age (147).  
The cytopathic effect induced by DAEC strains is distinguished by long cellular 
extensions that wrap around the adherent bacteria (159). 
 
Uropathogenic E. coli (UPEC) 
 There is a small number of O serogroups of E. coli that cause uncomplicated 
cystitis and acute pyelonephritis and this subset of E. coli is distinct from the commensal 
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E. coli strains found in the lower colon.  There is no single phenotypic profile that causes 
UTIs but specific adhesins and fimbriae aid in colonization (160, 161).  In addition, 
several toxins attributed to UPEC have been described, including cytotoxic necrotizing 
factor, haemolysin and the auto transported protease Sat (161).   
 
Meningitis/sepsis-associated E. coli (MNEC) 
 MNEC is the most common cause of Gram-negative neonatal meningitis (162, 
163).  Strains that cause meningitis are usually of the K1 capsule type and comprise only 
a small number of O serogroups.   
 
Mechanisms of antibiotic resistance 
 E. coli is often resistant to β-lactam antibiotics, this resistance is usually 
mediated by one or more β-lactamases enzymes (74, 164).  Ampicillin resistance is 
usually mediated by the OXA type of β-lactamases (79, 164).  Quinolone resistance is 
most often present in the form of alteration of the target of the quinolone molecule, DNA 
gyrase.  Aminoglycoside resistance is most often in the form of aminoglycoside 
modifying enzymes (165, 166).   
 
Klebsiella pneumoniae 
 
Microbiology 
 K. pneumoniae is a Gram-negative, non-motile, facultative anaerobic, 
encapsulated lactose fermenting bacteria.  The primary reservoir for K. pneumoniae is 
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humans, although it can be found in soil and water (167, 168, 169).  Carrier rates in 
humans ranges from 1 to 6 percent in the nasopharynx (although, higher rates have been 
seen in alcoholic patients), 5-38 percent in stools, and is rarely carried on skin (170).  
These carrier rates, however, are dramatically increased in hospitalized patients with 77, 
19 and 42 percent carrier rates in the stool, pharynx and hands, respectively (170).  
These higher rates of carriage are related to the use of antibiotics (170, 171).   
 
Disease 
 K. pneumoniae is most often described in patients with occupational exposure 
(often in the paper industry) (172) or as a nosocomial pathogen in patients with impaired 
host defenses such as alcoholism, malignancy, chronic obstructive pulmonary disease, 
glucocorticoid therapy, renal failure, diabetes mellitus, and hepatobillary disease (173, 
174, 175, 176, 177, 178).  In the nosocomial setting it has been associated with urinary 
and pulmonary tract infection, and bacteremia.  K. pneumoniae causes, although less 
commonly, community-acquired infection pneumonia, UTI, and a liver abscess 
syndrome (primarily in east Asia) that has been associated with metastatic infections.  
 
Pathogenesis 
 The pathogenesis of infection with K. pneumoniae is mediated by 5 major 
virulence factors: i) capsular serotype, ii) hypermucoviscosity, iii) lipopolysaccharide, 
iv) siderophores and v) pili (170).  There are 77 different serotypes of capsular 
polysaccharide antigens of K. pneumoniae, varying worldwide by region (179, 180, 181, 
182, 183, 184).  In human urine and sputum clinical isolates the most common serotype 
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for capsular antigen is the K2 serotype (179).  It has been demonstrated that the most 
common serotypes in Europe and North America are 2, 21 and 55 (179).  In contrast, the 
most common serotype in liver abscess, bacteremia and septic endophalmitis in Taiwan 
is K1 (178, 180-182, 183) and the most common serotype in Australia from urinary, 
sputum and blood isolates is K54 (183).  The K1 and K2 capsular polysaccharide antigen 
expressing isolates have been shown to have a higher lethality when administered to 
mice than the non-K1/K2 isolates (185).  The 2 major reasons for increased virulence of 
the K1/K2 serotype isolates are: i) these serotypes are more often hypermucoviscous 
then non K1/K2 strains and ii) the lack of mannose or rh-mannose sequences that protect 
the isolates from lectin mediated phagocytosis (186).   
 Isolates that have the hypermucoviscosity phenotype in K. pneomuniae are more 
resistant to complement-mediated serum killing than those lacking this phenotype (187, 
188).  Hypermucoviscosity has been shown to correlate to a higher rate of invasive 
infection when compared to non-invasive strains (187).  In addition, many clinical 
studies have shown a direct association between destructive tissue abscess syndrome and 
the hypermucoviscosity phenotype (181, 189, 190, 191). 
 The lipopolysaccharide O side chain can inhibit C1q and C3b in serum from 
binding to the K. pneumoniae cell membrane rendering it immune to complement-
mediated membrane damage (192, 193).  K. pneumoniae isolates that lack the 
lipopolysaccharide O side chain have been shown to have increased sensitivity to 
complement-mediated killing (192, 188, 193). In addition to inhibiting complement-
mediated killing, K. pneumoniae lipopolysaccharide can trigger cytokine pathways by 
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acting as an endotoxin leading to septic shock and an increase in the propensity for 
bacteremia (194).   
 Synthesis of siderophores is important to many bacteria, including K. 
pneumoniae, due to the low levels of iron present in the microenvironment of an 
infection (195).  The two main siderophores produced in K. pneumoniae are 
enterobactin, which is synthesized by most all strains, and aerobactin, which is found in 
less then 10 percent of strains (196, 197, 198).  K. pneumoniae strains that produce 
aerobactin are more virulent than those that do not, and it has been shown that the 
transfer of the aerobactin gene into a non-virulent K. pneumoniae strain can enhance 
virulence by 100-fold (199).   
 K. pneumoniae expresses 2 different types of pili, named type 1 and type 3 (200).  
Type-1 pili are found in all members of the Enterbacteriaceae and mediate adherence to 
epithelial cells (201).  The gene encoding these pili (fimH) is present in  more than 98% 
of K. pneumoniae (189, 202).  The type 3 pili contribute to virulence in K. pneumoniae 
by attaching to epithelial cells (203) leading to colonization and proliferation followed 
by infection.  In addition, type 3 pili are a requirement for K. pneumoniae to form 
biofilms (204).   
 
Mechanisms of antibiotic resistance 
 Drug resistance in K. pneumoniae is due to expression of chromosomal AmpC β-
lactamases that are constitutive and inducible, as well as plasmid-encoded ESBLs and 
carbapenemases.   
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Enterococci 
 
Microbiology 
 Enterococci are a Gram-positive facultative anaerobic organism that grows in 
chains and are distinguished by 4 criteria: i) react with group D antiserum, ii) 
demonstrate pyrrolidonyl arylamidase and leucine aminopeptidase, iii) grow in 6.5% 
sodium chloride and iv) hydrolyze esculin in the presence of bile.  Enterococci are a part 
of the normal intestinal flora and have recently become an issue as a multi resistant 
pathogen in the hospital setting (205, 206).   
 
Disease 
 Nosocomially, the most common infections due to enterococci are UTIs followed 
by intra-abdominal and pelvic infections (207).  Enterococci are also the causative agent 
in surgical wound infections, neonatal sepsis, meningitis, bacteremia, and endocarditis 
(208).   
 
Pathogenesis 
 Several studies have identified virulence factors in enterococci, the most 
important and prevalent being aggregation substance (AS), surface protein, gelatinase 
and fsr two-component system, pilli, MSCRAMMs (microbial surface components 
recognizing adhesive matrix molecules), CW and capsular polysaccharides, and 
glycolipids.  AS are a group of surface proteins that direct bacterial aggregation and 
whose expression is induced by a peptide pheromone (209, 210, 211).  In addition to 
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bacterial aggregation, AS have been reported to facilitate bacterial internalization (212, 
213, 214).  An enterococcal surface protein of great interest is the product of the gene 
esp (215, 216).  Proteins encoded by the esp gene have been identified as factors 
involved in colonization of the urinary tract (217).  Gelatinase is a secreted bacterial 
protease controlled by the fsr two-component system and has been shown to have an 
important role in biofilm formation (218).  The pilli of enterococci facilitate biofilm 
formation and adhesion, contributing to the pathogenesis of biofilm-associated diseases 
such as endocarditis (219) and UTIs (220, 221). MSCRAMMs contribute to 
pathogenesis of enterococci by interacting with the extracellular matrix leading to 
colonization of human tissues.  The CW of enterococci is important for virulence 
because it prevents complement activation and killing by phagocytes through evasion of 
the host’s immune system (222).  Glycolipids play an important role in virulence and are 
involved in forming a permeable layer between the cytoplasm of the host cell and the 
environment (223, 224).     
 
Mechanisms of antibiotic resistance 
 Enterococci have an intrinsic resistance to low levels of aminoglycosides and 
clindamycin, nalidixic acid, lincosamides, low levels of penicillinase susceptible 
penicillin, penicillinase resistant penicillins and cephalosporins (225). Because their 
penicillin binding proteins (PBP’s) are low affinity, the enterococci retain their ability to 
synthesize the CW in the presence of these antibiotics (225).  In addition to intrinsic 
resistance to β-lactams, enterococci can become tolerant to penicillin in as few as 5 
doses (207) and can produce β-lactamase enzymes (225-227, 228).  Low-level resistance 
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to aminoglycosides is a trait shared by all enterococci and is attributed to low uptake of 
these molecules (225).  Enterococci can acquire high level aminoglycoside resistance 
through the expression of AMEs that are transferable from one organism to another the 
most common of which are (i) dual function 2’phosphotransferase and 6’acetyl 
transferase that confer resistance to all aminoglycosides except streptomycin, (ii) 
3’phoshotransferase which confers resistance to kanamycin and penicillin-amikacin, (iii) 
6’adenyl transferase which inactivates streptomycin (225).  An important clinical 
problem is the rapid spread of enterococci that have also become resistance to 
glycopeptides (229, 230-232) following the first report of vancomycin-resistant 
enterococci (VRE) in the 1980s (233).  Most commonly resistance to glycopeptides in 
enterococci has been reported in 3 phenotypes i) Van A which is inducible and confers 
high level resistance to vancomycin and teicoplanin, ii) Van B which confers varied 
levels of resistance to vancomycin and is sensitive to teicoplanin and iii) Van C which 
confers constitutive low level resistance to vancomycin and sensitivity to teicoplanin 
(234, 235). 
 
Staphylococcus aureus 
 
Microbiology 
 S. aureus is  Gram-positive, catalase and coagulase positive, mannitol 
fermenting, non-motile common commensal organism found in 30-50% of healthy 
humans.  S. aureus is an aerobic organism but can tolerate growth at low oxygen, under 
high osmotic pressure and at a wide temperature range (236). 
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Disease 
 Although S. aureus is a common commensal, it is also an opportunistic pathogen 
that can cause many diseases in humans and other species.   Infections caused by S. 
aureus range from mild skin diseases to invasive illness (236).  Prolonged infections 
lead to development of osteomyelitis or necrotizing fasciitis (237, 238).  S. aureus sepsis 
is usually associated with bacteremia, and can be secondary to bacterial infection of the 
urinary tract, bone, kidney, or lungs (239, 240).  S. aureus is a causative agent of toxic 
shock syndrome (TSS) and gastroenteritis (241).  In addition, S. aureus is the most 
frequently isolated pathogen from patients suffering from ventilator-associated 
pneumonia (242).   
 
Pathogenesis 
 S. aureus possesses both secreted and structural products that contribute to its 
virulence and pathogenesis.   It has a variety of surface attachment-improving agents 
known as MSCRAMMs that mediate attachment to host cells and therefore initiate 
colonization. S. aureus exotoxins and super antigen toxins have been implicated in 
gastroenteritis and TSS (243).   
  
Mechanisms of antibiotic resistance 
 Methicillin resistant S. aureus (MRSA) accounts for the majority of nosocomial 
infections (244).  Nosocomial strains of methicillin resistant S. aureus known as 
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hospital-associated S. aureus (HA-MRSA) infects those that have established risk factors 
such as prolonged hospitalization or antimicrobial therapy, surgical procedures, dialysis, 
indwelling vascular devices, and proximity to patients in the hospital who are infected or 
colonized with MRSA (236). HA-MRSA strains are usually resistant not only to 
methicillin but also to many classes of antibiotics (245).  MRSA infecting individuals 
outside of the healthcare facilities is referred to as community-associated MRSA (CA-
MRSA) (246, 247). Contrary to HA-MRSA, CA-MRSA strains are mostly resistant to β-
lactams (248). Although CA-MRSA is traditionally less drug resistant, clusters of 
disease of a multidrug-resistant USA300 isolates that contain multiple resistance genes, 
rendering it resistant to β-lactams, fluoroquinolones, tetracycline, macrolide, 
clindamycin, and mupirocin, surfaced in the community (249, 250).   
 Daptomycin is a lipopeptide antibiotic that was approved by the United States 
Food and Drug Administration (FDA) in 2003 for treatment of complicated skin and soft 
tissue infections caused by bacteria, including methicillin-resistant Staphylococcus 
aureus (Cubist Pharmaceuticals, Inc. 2003. (Daptomycin (Cubicin) package literature, 
Cubist Pharmaceuticals, Inc., Lexington, Mass.).  However, treatment failure due to 
daptomycin resistance has been recently reported (251).   
 
Antimicrobial peptides (AMPs) 
  
 AMPs are short amino acid sequences derived from larger precursors. They are 
present in many organisms ranging from prokaryotes to humans. These peptides have an 
ancient lineage and are widespread throughout the plant and animal kingdoms, which 
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suggests that they have played an integral part in the evolution of multicellular 
organisms. These peptides are used as potent broad-spectrum antimicrobial agents with a 
diverse range of targets; the presence of a lipid membrane being the only common 
characteristic among their targets (252, 253, 254).  AMPs are one of the earliest 
developed molecular effectors of innate immunity, and beyond antimicrobial effects, 
these peptides have been shown to confer many functions in wound healing (255), 
chemotaxis (256), and the induction of adaptive immune responses to foreign antigens 
(257). Almost all antimicrobial peptides share a common composition consisting of 
hydrophobic and hydrophilic cationic amino acids that confer an amphipathic structure 
(258).  
 Amphipathic alpha helices have been reported in a variety of proteins (259) and 
are defined by their opposing polar and non-polar faces oriented along a helical axis. 
These helices make up 50% of the alpha helices found in soluble globular proteins (260, 
261). There are a variety of purposeful characteristics attributed to this class of helices, 
such as lipid association, membrane perturbation, hormone-receptor catalysis, 
transmembrane signal transduction, regulation of kinase-calmodulin signal transduction 
and transmembrane helical bundle formation (259).   
 AMPs are divided into 5 major groups according to their amino acid composition 
and structure (262, 263, 261).  The first class of AMPs known as the anionic peptides are 
small peptides present in surfactant extracts, airway epithelial cells and bronchoalveolar 
lavage fluid (261, 264, 265).  These anionic peptides require zinc as a cofactor and are 
active against both Gram-negative and Gram-positive bacteria. Cationic peptides are 
enriched for a specific amino acid. These peptides lack cysteines and are mostly linear 
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although some form extended coils.  There is also a subgroup of anionic and cationic 
peptides that contain cysteines and form disulphide bonds and stable β-sheets. This 
group of AMPs covers human and insect defensins. An additional subgroup includes 
anionic and cationic peptides that are fragments of larger proteins.  These are similar in 
structure and composition to the other classes of antimicrobial peptides but their role in 
innate immunity is not clear.  The final class of antimicrobial peptides are the linear 
cationic α-helical peptides, which usually contains less then 40 amino acids and can have 
a hinge or ‘kink’ in the middle (266, 267).  When in an aqueous environment, these 
peptides are highly disordered; however, when in the presence of SDS micelles, lipid A, 
phospholipid vesicles and liposomes, these peptides will convert into an alpha helix 
(262).  
 The mechanism of action of amphipathic AMPs has been fairly well defined 
(268).  Three main steps must take place for AMP-mediated cell killing to occur: (i) 
attraction of the peptide to the cell surface, (ii) attachment of the peptide to the 
cytoplasmic membrane and (iii) peptide insertion followed by membrane 
permeabilization.  There are 6 main characteristics that affect antimicrobial activity and 
specificity: size, sequence, charge, conformation and structure, hydrophobicity and 
amphipathicity.  Currently, there are three widely accepted models of peptide insertion 
and permeabilization of the membrane (Fig. 1-3, (268)). The carpet model describes the 
parallel attachment of the peptides to the surface of the lipid bilayer where the anionic 
phospholipid head groups on the outer surface of the membrane form a thick layer or 
‘carpet’ (269).  At high concentrations these peptides are proposed to disrupt the 
membrane, similar to detergent forming micelles (270, 271), leading to the loss of  
  33 
 
Figure 1-3.  Modes of action of 
antimicrobial peptides.   
(A) Carpet model.  
“In this model, the peptides disrupt the 
membrane by orienting parallel to the 
surface of the lipid bilayer and forming an 
extensive layer or carpet. Hydrophilic 
regions of the peptide are shown coloured 
red, hydrophobic regions of the peptide are 
shown coloured blue”   
(B) Barrel stave model.   
“In this model, the attached peptides 
aggregate and insert into the membrane 
bilayer so that the hydrophobic peptide 
regions align with the lipid core region and 
the hydrophilic peptide regions form the 
interior region of the pore. Hydrophilic 
regions of the peptide are shown coloured 
red, hydrophobic regions of the peptide are 
shown coloured blue.”  
(C) Torodial pore model.   
“In this model the attached peptides 
aggregate and induce the lipid monolayers 
to bend continuously through the pore so 
that the water core is lined by both the 
inserted peptides and the lipid head groups. 
Hydrophilic regions of the peptide are 
shown coloured red, hydrophobic regions of 
the peptide are shown coloured blue.”  
 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews 
Microbiology (Brogden, 2005) copyright (2005).   
A  B 
C 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membrane integrity (Figure 1-3A; (268)). The barrel stave model (Figure 1-3 B, (268)) 
consists of the insertion and aggregation of the peptides in the lipid bilayer. The 
aggregation results in the formation of a pore where the hydrophilic regions of the 
peptide lies in the inner core of the aperture (268). The third proposed mechanism of 
action is the toroidal pore model (Figure 1-3C, (268)). In this model, the peptide attaches 
to the surface of the membrane, aggregates and induces bending in the lipids so that the 
interior of the pore is lined with the lipid head groups and the inserted peptide (272).  
Although these three theoretical models seem distinct, it has been proposed that they are 
likely related and peptide concentration (273).  
 
Modified peptides in current use and testing 
 There are many examples of modified host defense peptides and synthetic AMPs 
that have entered into human testing (274, 275). Currently, there are 12-15 in different 
stages of clinical development (275) however, the only peptide antibiotics currently used 
are Polymyxin B/E, Gramicidin S and daptomycin.  Unfortunately, both the polymyxins 
and Gramicidin S are only used topically and not used systemically because they have 
been shown to be extremely toxic (275).  There has been an effort to modify both 
peptides to make them less toxic and although it has not been successful for Gramicidin 
S there is a modified form of Polymyxin that is currently used systemically for lung 
infections of CF patients (275).  The FDA, however, approved Daptomycin, in 2003 for 
the treatment of skin and skin-suture infections caused by susceptible Gram-positive 
organisms.   
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Daptomycin  
 Daptomycin is a 13-member amino acid cyclic lipopeptide with a decanoyl side-
chain (276) that has bactericidal activity against Gram-positive organisms. Daptomycin 
is produced by Streptomyces roseosporus as a fermentation product (277-280, 281).  The 
proposed mechanism of action of Daptomycin is identical to that of antimicrobial 
peptides described previously, insertion into the bacterial cell membrane causing 
depolarization, although the proposed method of cellular death is arrest of DNA, RNA 
and protein synthesis (276, 282), not cell lysis. 
 
KLA peptides  
 One type of peptide that has been thoroughly studied is a group of α-helical 
amphipathic peptides derived from the model peptide KLALKLALKALKAALKLA-
NH2 originally used for studying the interactions between peptides and lipid interfaces 
(283, 273, 284, 285, 286, 287, 288).  These derivatives are collectively called the KLA-
derived peptides. 
 (KLAKLAK)1-3  is a KLA-peptide that was originally tested for its ability to kill 
both eukaryotic and prokaryotic cells by the McLaughlin group in 1996 (289).  
Jadvapoor et al. designed several different KLA-peptides to determine the effect of 
length, sequence, and structure on biological activity. It was found that all of the leucine- 
and alanine-containing peptides of the same length had similar MIC values. In addition, 
it was shown that the 7-mers were inactive and the leucine-containing 21-mers were 2 
times as potent at killing bacteria as the 14-mers, while maintaining low mammalian-cell 
toxicity (289).   
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Obstacles for clinical use of antimicrobial peptides  
 The major issues for clinical use of AMPs as antibiotics are the same issues faced 
with development of most forms of antibiotics: (i) high cost of commercial scale 
synthesis, (ii) toxicity, (iii) proteolytic degradation/inactivation, (iv) resistance and (v) 
poor distribution in the body. The first issue, cost of synthesis, is important to consider 
because production costs for peptides is generally higher than the cost to produce 
‘conventional’ antibiotics. Toxicity is important to consider because for an antibiotic to 
be effective it must be highly selective towards bacterial cells while having minimal 
toxicity against eukaryotic cells.  Often AMPs have considerable hemolytic activity 
(290) which hinders their use as systemic antimicrobials, and restricts their use to topical 
applications.  Development of peptides that have a reduced toxicity and enhanced 
antimicrobial activity is possible with the understanding of features that lead to 
selectivity of the peptide. Proteolytic degradation of AMPs is a common problem, with 
most peptides being degraded, or bound by proteins in the blood stream and therefore 
rendered inactive. Commonly, peptide structures are modified so that they are no longer 
recognized or degraded by proteolytic enzymes (291).  This approach has been 
successful with a number of peptides including magainin analogues (292) where 
tyrosines are substituted with β-tyrosines that are shortened by one carbon unit in the 
side chain.  The substitution allows the peptide to have the same structure as the 
naturally occurring peptide as well as have a greater stability.  It can be assumed that if 
peptide interaction with bacterial membranes leading to lysis of bacterial cells is 
membrane receptor dependant, then that receptor would require a specific chirality of the 
peptide to be functional.  However, it has been shown that the enatiomeric forms of 
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AMPs with all D-amino acids have equal activities when compared to their L 
counterparts (293, 294, 295). Additionally, D-form AMPs have a higher stability against 
proteolytic degradation (296, 297). 
 The issue of resistance is not as serious of a concern with AMPs because it is 
assumed that resistant strains will not easily arise because the target of most AMPs is the 
bacterial membrane, a structure that it is essential for the bacterium’s survival.  This 
assumption is strengthened by the observation that AMPs have been found in organisms 
for millions of years with only a few incidences of resistance ever demonstrated.   
 Poor distribution of AMPs this can be overcome with site-specific administration 
and targeting of the peptides.   
 
Significance of this research 
  
 Currently, it is estimated by the National Institute of Allergy and Infectious 
Disease that over 70% of hospital-acquired infections are resistant to at least one of the 
antibiotics used to treat them.  Routine use of antimicrobial agents has reduced the threat 
posed by infectious diseases and--along with improvements in sanitation, housing, 
nutrition, and wide-spread immunization programs--has led to a marked reduction in 
deaths from diseases that were previously widespread, untreatable, and frequently fatal.  
However, the overuse and misuse of these antimicrobial agents has lead to an increase in 
resistant organisms, which have spread through many hospitals and communities.  
According to NIH estimates, between 5-10% of all hospital patients develop an 
infection, leading to an increase of about $5 billion in annual U.S. healthcare costs.  
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 The rise of multi-drug resistance represents a clear need for new, novel 
antibiotics to combat these resistant infections; however, antimicrobial research and 
development of new antibiotics is lagging far behind the ability of organisms’ ability to 
acquire resistance.  In the 1930s and 1940s there were 4 new classes of antibiotics 
introduced: sulphonamides, β-lactams, aminoglycosides and chloramphenicol.  
Following these developments in the 1950s and 1960s there were 6 more classes of 
antibiotics that were developed and approved: tetracycline, macrolides, glycopeptides, 
rifamycins, quinolones and Trimethoprim.  Following 4 decades of initial discovery, 
from the 1970s to the 1990s there were no new antimicrobial classes approved, and since 
2000 there has only been approval for a few new classes of antimicrobials: 
oxazolidinones, cyclic lipopeptides and glycylcyclines, all of which are approved for the 
treatment of Gram-positive pathogens.    The time required to take an antibiotic from its 
discovery to market is around 8-12 years (298).  Although there is a limited number of 
antimicrobial agents recently approved or in the late stages of development, these are 
directed solely toward Gram-positive pathogens leaving a lack of antibiotics in the 
development stages to take on the present problem of multi-resistant Gram-negative 
pathogens (299, 300).  The current options to treat MDR infections are becoming limited 
as these bacteria expand their ability to evade existing antibiotics by developing of 
various resistance mechanisms.  Organisms of great concern due to the ability to become 
multi-resistant are P. aeruginosa, K. pneumoniae, E. coli, E. faecalis, A. baumannii and 
S. aureus.   
 In this study we have shown that a synthetic AMP able to disrupt bacterial 
membrane non-specifically is active against Gram-negative organisms such as P. 
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aeruginosa, K. pneumoniae, E. coli and A. baumannii, regardless of their antibiotic 
resistance profiles. Although the scientific community does not see development of 
resistance to AMPs as a concern, reduced sensitivity of S. aureus and E. faecalis to de-
novo AMP, DAP, emerged as a result of treatment.  Resistance associated with DAP 
include, most importantly, modifications to the thick peptidoglycan layer surrounding 
the CM of Gram-positive organisms. Since this is a Gram-positive specific cell feature, 
the mechanism of resistance related to changes in the peptidoglycan layer is also specific 
to Gram-positive cells.   
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Materials and Methods 
 
Media and growth conditions: 
Gram-negative bacterial isolates. P. aeruginosa 10145, A. baumannii 19606 and E. 
coli strain 25922 were obtained from ATCC. Pseudomonas aeruginosa PAO1 and PA14 
were provided by Dr. Frederick M. Ausubel, Harvard University. Gram-negative clinical 
isolates were provided by the Clinical Microbiology Laboratory at St. Lukes Episcopal 
Hospital. All strains were grown at 37°C in cation-adjusted Mueller Hinton broth (CA-
MHB) unless otherwise stated.  The biofilm inhibition assays were performed in CA-
MHB and 10% FBS-RPMI.  
 
E. faecalis bacterial isolates. The two vancomycin-resistant E. faecalis isolates used 
were recovered from the bloodstream of a 64-year-old woman (301). The first isolate 
(daptomycin-susceptible) was recovered after the administration of linezolid and 
ciprofloxacin (daptomycin MIC, 1 µg/ml). The second isolate (daptomycin MIC 16 
µg/ml) was obtained from the blood of the same patient two weeks after the start of 
daptomycin and amikacin therapy. The daptomycin resistant isolate exhibited the same 
pulsed field gel electrophoresis pattern and had identical susceptibilities to antibiotics as 
the parental susceptible isolate, except for daptomycin (301). Both isolates were grown 
in brain heart infusion broth. 
 
D(KLAKLAK)2 was obtained from Poly-Peptide-Labs. 
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Stability assays.  The stability of D(KLAKLAK)2 compared to L(KLAKLAK)2 in the 
presence of human liver microsomes was determined by mass spectrometry . Briefly, 5 
µl of human liver microsomes (pooled from multiple donors; BD Biosciences) were 
diluted in 75 µl of 50 mM potassium phosphate buffer pH 7.4.  D(KLAKLAK)2 and 
L(KLAKLAK)2 were added to the mixture (10 µl of a 10 mg/ml solution in water) and 
warmed for 5 minutes at 37°C.  The reaction was started with the addition of 10 µl of 20 
mM NADPH in phosphate buffer.  Aliquots (10 µl) were removed pre- and post-addition 
of NADPH at 1, 10, 30 and 60 minutes and 24 hours.  The reactions were stopped with 5 
µl of 100% trifluroacetic acid. All samples were frozen at -80°C until processed by 
matrix assisted laser desorption/ionization time-of-flight (MALDI) with double time-of-
flight (TOF2) detection. 
 
MALDI-TOF2 mass spectroscopy.  The samples were centrifuged at 13,200 rpm for 30 
minutes at 4oC to remove liver microsomal debris and then 2 µl of each sample was 
added to 198 µl of 0.1% TFA solution. Samples were then further diluted 1:10 in α-
cyano-4-hydroxyl cinnamic acid (αCHCA; 10 mg/ml in 50% acetonitrile 0.5% TFA). 
Each sample was loaded to 3 spots on a MALDI-TOF plate and MS data acquired on 
each spot in duplicate. 13C-D(KLAKLAK)2 was used as the internal standard for 
quantification. Quantification was performed by integrating the peak area of individual 
spectra and was graphically displayed relative to the internal control. 
 
Susceptibility assays (MIC). Antimicrobial susceptibility testing was performed as 
recommended by the NCCLS (CLSI document M100-S16 CLSI).  All bacterial isolates 
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were tested by broth micro dilution in CA-MHB.  After incubation for 18h at 37°C, the 
MIC is defined as the lowest concentration of the antimicrobial agent that inhibits visible 
growth of the tested isolate as observed with the unaided eye. All experiments were 
performed in triplicate.    
 
Time-kill curves. Overnight bacterial cultures were diluted in fresh medium, and 
allowed to reach exponential phase of growth. Increasing concentrations of peptide 
and/or antibiotic were added and the cultures were incubated at 37°C with shaking for up 
to 24 hours. To determine viable bacteria, aliquots were taken at 4, 10 and 24 h after 
treatment and dilutions were plated onto LB agar. The plates were incubated at 37°C and 
the colony forming units (CFU) were counted after 24 h.  All assays were performed a 
minimum of 3 times with representative data shown. 
 
Synergistic assays.  The synergistic activity between D(KLAKLAK)2 and piperacillin 
was assayed by time kill curves in CA-MHB as described earlier (302). Briefly, the 
samples were set up using concentrations of D(KLAKLAK)2 and piperacillin at ½ the 
MIC, as determined by broth dilution.  One sample of each D(KLAKLAK)2 alone, 
piperacillin alone, D(KLAKLAK)2 and piperacillin together and a control with no 
antibiotics were assayed.  
  
Biofilm assays. P. aeruginosa PAO1 biofilm was grown as described previously (303). 
Briefly, PAO1 overnight culture was diluted 1:100 in LB or 10% FBS RPMI into 96-
well plates and incubated for 24 hrs at 37°C without agitation. To assess the effect of 
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D(KLAKLAK)2 treatment on the biofilm, increasing concentrations of peptide diluted in 
LB or 10% FBS RPMI were added to the 24hr-old biofim. The next day, P. aeruginosa 
biofilm was fixed with 4% paraformaldehyde and stained with 0.1% crystal violet (CV) 
for 10 min at room temperature. Excess stain was removed with water and the plates 
were dried overnight at room temperature. CV stain was dissolved in 95% ethanol and 
the absorbance of a 1:5 a dilution in 95% ethanol was measured at 540 nm.  All assays 
were performed a minimum of 3 times with mead of the 3 experiments shown. 
 
Growth phase-dependent activity.  The ability of D(KLAKLAK)2 to induce membrane 
permeability was investigated using the highly sensitive Baclight kit (Invitrogen). 
Overnight cultures of P. aeruginosa PAO1 and PA14 were diluted 1:100 in media.  Six 
milliliter aliquots were removed before resuspension (stationary phase), 30 minutes after 
resuspension  (lag phase), 1h after resuspension (early exponential phase) and 2 hours 
after resuspension (late exponential phase).  Bacteria were washed in PBS and treated 
with increasing concentration D(KLAKLAK)2 or 70% isopropanol. After 1 hour, bacteria 
were collected, washed and resuspended to OD600 of 0.03. An equal mixture of SYTO9 
and propidium iodide (3ul) was added to each 1 ml of sample.  The samples were 
incubated 15 minutes at room temperature in the dark. Images were acquired on an 
Olympus IX71inverted microscope attached to a Lumen 200 Fluorescene Illumination 
system with fluorescein and Texas Red bandpass filter sets made by Prior Scientific. 
 Images were collected on the Slidebook 5.0 software.    
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P. aeruginosa electron microscopy.  P. aeruginosa was grown to McFarland’s standard 
0.5 as described above.  Bacterial cells were recovered by centrifugation, resuspended in 
saline and treated with freshly prepared D(KLAKLAK)2 at varying concentrations.  The 
organisms were exposed to D(KLAKLAK)2 for 25 minutes. Bacteria were collected, 
washed and fixed with a solution containing 3% gluteraldehyde plus 2% 
paraformaldehyde in 0.1 M cacodylate buffer, pH 7.3. After fixation, the samples were 
washed in 0.1 M cacodylate buffer, postfixed in 4% Millipore-filtered potassium 
permanganate for 1 hour, washed in distilled water and stained en bloc with 1% 
Millipore-filtered aqueous uranyl acetate for 1 hour. The samples were dehydrated in 
increasing concentrations of ethanol, three changes in propylene oxide, infiltrated and 
embedded in LX-112 medium. The samples were polymerized in a 70° C oven for 3 
days.  Ultrathin sections were cut in a Leica Ultracut microtome (Leica, Deerfield, IL), 
stained with uranyl acetate and lead citrate in a Leica EM Stainer, and examined in a 
JEM 1010 transmission electron microscope (JEOL, USA, Inc., Peabody, MA) at an 
accelerating voltage of 80 kV. Digital images were obtained using the AMT Imaging 
System (Advantage Microscopy Techniques Corp., Danvers, MA). 
 
E. faecalis electron microscopy.  DAP-sensitive and DAP-resistant ultrastructural 
characteristics were assessed by transmission electron microscopy (TEM).  Bacteria 
were collected, washed and fixed with a 3% gluteraldehyde and 2% paraformaldehyde in 
0.1 M cacodylate buffer, pH 7.3.  Samples were incubated for 5 min in Millonig’s 
solution followed by a 45 min incubation in 50/50 OsO4 /Millonigs solution. After 5 min 
in ddH2O, samples were step-wise dehydrated using increasing concentrations of ethanol 
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solutions as follows: 5 min in 50% ethanol, 10 min in 70% ethanol, 10 min in 95% 
ethanol, washed 3 times for 10 min in 100% ethanol.  Dehydrated samples were washed 
3 times for 10 min in propylene oxide, followed by incubation in 50% LX-112 for 120 
min, then 100%  LX-112 for 120 min and were imbedded in BEEM capsules and 
incubated in a 70o C oven overnight to polymerize.  To section the tissue, 500 nm 
sections were cut from each block using a glass knife on a Leica Ultracut R microtome 
and were stained with 0.5% Toluidine Blue for 1 minute on a hot plate at 80 °C. Slides 
were washed and inspected for fitness.  The best blocks were then trimmed and thin 
sections (80 nm & 100 nm) were cut using a DiATOME diamond knife, one each of the 
two thicknesses were floated on either 100 or 150 mesh copper grids (Electron 
Microscopy Sciences) and heat fixed in a 70 °C oven for at least one hour. The grids 
were stained for 15 minutes using 2% uranyl acetate, rinsed with ddH2O, stained 5 
minutes in Renold's lead citrate, rinsed and dried in 70 °C oven. The specimen grids 
were imaged in a JEOL 1200 transmission electron microscope at 60kV with digital 
images collected using a 1k X 1k Gatan BioScan camera, Model 792, on a JEOL JEM-
1400 cryo-transmission electron microscope.  To quantify the number of cell division 
events (cells with a septum), cells were counted in 5 random consecutive fields in two 
blinded experiments. Similarly, the average cell wall thickness was determined by 
measuring a minimum of 3 times per cell on cells in 5 different fields.  CW thickness 
was measured from the outer border of the CM to the outer edge of the CW. Mean (+ 
SD) CW thickness was determined for each strain and mean differences compared with a 
t-test.   
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Liposome Formation.  E. coli extract, 1,2-distearoyl-sn-glycero-3-phospho-L-serine 
(PC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (PE), 1,2-dioleoyl-sn-glycero-3-
phosphatidylglycerol (PG), 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (PS),  
cholesterol, N-(7-nitro-2,1,3-benzoxaidasol-4-yl)-PE (NBD-PE) and N-(rhodamine B 
sulfonyl)-PE (Rh-PE) were procured from Avanti Polar Lipids (Alabaster, AL).  All 
phospholipids were used without additional purification. The fluorescent dyes were 
dissolved together with unlabeled lipid.  Solvent was evaporated under a steady stream 
of argon.  After the solvent evaporation, lipids were resuspended to a concentration of 
1mg/mL in PBS and sonicated for 10 minutes. Subsequently, the preparation was stored 
at 4°C until use. For the FRET measurements liposomes were made with 5% fluorescent 
lipid (NBD-PE or Rh-PE) and 95% unlabeled lipid, by weight. For specific lipid 
interactions, increasing weight percentages of PC, PS, PE, or PG were added to E. coli 
extract. All assays were performed in triplicate with average and standard deviation 
shown. 
 
Flourescence resonance energy transfer (FRET).  To determine the ability of 
D(KLAKLAK)2 to disrupt liposomal membranes, increasing peptide concentrations 
where added to an equal mixture of Rh-labeled and NBD-labeled liposomes. After 24 h, 
fluorescence transfer was measured using a Spectramax M5 spectrophotometer. The 
excitation wavelength was 460 nm (excitation wavelength of NBD-PE) and the emission 
spectrum was measured between 500-620 nm (534 nm emission of NBD-PE and 590 nm 
emission of Rh-PE) with bandwiths: excitation 9 nm and emission 15 nm. 
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GUV formation. A thin film (~300 µL) of 1% agarose in deionized water was spread 
onto a glass slide and then dried at 40°C for 3 hours. A mixture of E. coli extract and Rh-
PE (30 µl) in chloroform was painted across the agarose film and allowed to dry under 
vacuum pressure for 2h.  Slides were then placed into 150 mM KCL buffer and the 
agarose was allowed to re-hydrate for a minimum of 1h. Pictures were taken 5 seconds 
after the addition of D(KLAKLAK)2. Diluent alone (KCl buffer) was used as negative 
control. All assays were performed a minimum of 3 times with representative data 
shown. 
 
Gram-negative membrane potential measurements.  Bacteria were collected from a 
mid-exponential culture, washed in buffer (5mM HEPES pH 7.2, 5mM glucose), and 
resuspended in the same buffer to OD600nm of 0.05. diSC3(5) and EDTA were added to 
the bacterial suspension at final concentrations of 0.4 µM and 0.2 mM EDTA, 
respectively. The mixture was incubated in the dark for 1h to allow maximal uptake of 
the diSC3(5). The osmotic gradient was equilibrated to a final concentration of 100 mM 
KCl.   Subsequently, the mixture was subjected to increasing concentrations of 
D(KLAKLAK)2  in buffer. diSC3(5) fluorescence was monitored using a Spectramax M5 
spectrophotometer at excitation of 622 nm and emission of 670 nm. Relative 
fluorescence intensities were normalized to the effect of PBS, which was assigned a 
value of 0% and 100% isopropanol, which was assigned a value of 100%.  All assays 
were performed a minimum of 3 times with representative data shown. 
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Gram-negative outer membrane permeability.  A 5mL overnight culture of bacteria 
was used to inoculate 50 mL of LB broth. Mid-log phase bacteria were collected, 
washed once and resuspended in HEPES buffer (5mM (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) HEPES pH 7.2, 5 mM sodium azide) to a final 
concentration OD600nm of 0.5. The bacterial suspension was added to a clean plastic 
cuvette and the OD600nm was measured for 10 s. Lysozyme was then added to a final 
concentration of 50 µg/mL and the OD600nm was measured for an additional 10 s. 
Subsequently, increasing concentrations of D(KLAKLAK)2 in small increments (5-10 µL 
at a time) were added to the sample.  The turbidity of the sample was measured after the 
lysis process stabilized (as seen by a stabilization in the OD600nm) and every 10 seconds 
after stabilization for 30 seconds.  Relative values were normalized to the effect of PBS, 
which was assigned a value of 0% and 100% isopropanol, which was assigned a value of 
100%.  All assays were performed a minimum of 3 times with representative data 
shown. 
 
Erythrocyte hemolysis. Whole human blood was collected in EDTA and erythrocytes 
were separated by centrifugation. The cells were washed with 150 mM NaCl, and 
resuspended in PBS at a concentration of 108 erythrocytes/mL. The erythrocyte 
suspension was incubated at 37°C with increasing concentrations of D(KLAKLAK)2. 
After centrifugation, the hemoglobin released in the supernate was measured at 415 nm 
after 48h.  All assays were performed in triplicate with mean and standard error of the 
mean shown.   
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Surface charge in E. faecalis pair.  Cell surface charge was measured using a modified 
cytochrome c assay as described previously (304).  Briefly cells were grown overnight in 
brain-heart infusion broth (BHI), washed twice with 20 mM 3-(N-morpholino) 
propanesulfonic acid (MOPS) buffer pH 7, and resuspended in the same buffer.  Cells 
were then incubated with 0.5 mg/ml cytochrome c for 10 minutes, pelleted and the 
amount of cytochrome c remaining in the supernatant was determined 
spectrophotometrically at 530 nm (the lower the amount of bound cytochrome c, the more 
positively charged the cell envelope).  All assays were performed in triplicate with 
average and standard deviation shown. 
 
CM permeabilization in E. faecalis pair.   The highly sensitive LIVE/DEAD BacLight 
kit was used in order to measure DAP-mediated CM permeabilization.  Cells were grown to 
mid-exponential phase in BHI, harvested and washed once in HEPES buffer (5mM 
HEPES, 5mM glucose pH 7.2), then resuspended in the same buffer containing 5µM 
SYTO-9, 30 µM propidium iodide and 50 mg/L calcium.  Cells were allowed to 
equilibrate for 10 min at room temperature and were added to 96-well plate with 
increasing concentrations of DAP. Fluorescence was measured immediately with an 
excitation wavelength of 488 nm and emission wavelength of 510 nm on a fluorescence 
spectrophotometer. A negative control of buffer and a positive control of 100% 
isopropanol were included.  Percent fluorescence change was calculated setting 
isopropanol control as 100% fluorescence change and buffer as 0% fluorescence change.  
All assays were performed in triplicate with average and standard deviation shown. 
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CM depolarization in E. faecalis pair.   We also monitored the effect of DAP on CM 
potential (ΔΨ) using diSC3(5) using the protocols described above with the following 
modification: all assay buffers contained 50mg/L calcium.  All assays were performed in 
triplicate with average and standard deviation shown. 
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Chapter III 
D(KLAKLAK)2: A Membrane Active Anti-Gram Negative Peptide 
 
Introduction 
 (KLAKLAK)2  is a KLA-peptide that was originally assessed by the McLaughlin 
group for its ability to kill both eukaryotic and prokaryotic cells (289).  Jadvapoor et al. 
designed several different amphipathic helical peptides with the sequences: 
(KLAKKLA)n, (KLAKLAK)n (where n = 1,2,3), (KALKALK)3, (KLGKKLG)n, and 
(KAAKKAA)n (where n = 2,3) to determine the effect of length, sequence, and structure 
on biological activity. It was found that all of the leucine- and alanine-containing 
peptides of the same length had similar MIC values. In addition, it was shown that the 7-
mers were inactive and the leucine-containing 21-mers were 2 times as potent at killing 
bacteria as the 14-mers, while maintaining low mammalian-cell toxicity (289). Peptide 
cytotoxicity against human erythrocytes and 3T3 mouse fibroblasts and antibacterial 
activity against E. coli, P. aeruginosa, and S. aureus was tested. All of the leucine- and 
alanine-containing peptides of the same length were found to have similar MIC values 
and it was also found that the peptides were much less lytic toward human erythrocytes 
than 3T3 cells. Since the first description, (KLAKLAK)2 has been widely used in cancer 
research (305, 306, 307, 308, 309) as a pro-apoptotic moiety. Once internalized into 
eukaryotic cells, AMPs such as (KLAKLAK)2 cause mitochondrial disruption by 
triggering membrane permeabilization and swelling, resulting in release of cytochrome c 
and induction of apoptosis (306). 
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 Here, we show that (KLAKLAK)2, is an effective antimicrobial against Gram-
negative laboratory strains and clinical isolates. Despite the therapeutic promise, AMPs 
development is hindered by their susceptibility to proteolysis. Here, we demonstrated 
that an all-D enantiomer of (KLAKLAK)2, resistant to proteolysis,  retains its activity 
against Gram-negative pathogens. In addition, we have elucidated the specific site and 
mechanism of action of D(KLAKLAK)2 through a repertoire of whole-cell and model 
membrane assays. 
 
Results 
D(KLAKLAK)2 peptido-mimetic is proteolytically stable 
 We used mass spectrometry to determine the stability of D(KLAKLAK)2 
compared to L(KLAKLAK)2 in the presence of human liver microsome extracts 
containing Cytochrome P450 (CYP450), the major enzyme complex involved in drug 
metabolism. To control for specificity, reactions were carried out in the presence or 
absence of the NADPH co-factor. (KLAKLAK)2 peptide degradation in the absence of 
NADPH would indicate metabolism from enzymes other then CYP450. Intact 
D(KLAKLAK)2 was detected after 0, 30, 60 minutes and 24 hours confirming its 
prolonged stability after continuous exposure to proteases (Fig. 3-1).  All samples co-
incubated with NADPH contained a small amount of an unidentified adduct at +258 
amu. A significant amount of an unidentified adduct at +105 amu was found after 24 
hours specifically in the samples containing NADPH. (Fig. 3-2 and 3-3). 
 Contrastingly, the concentration of L(KLAKLAK)2 decreased over time and it 
was completely degraded after 24 hours of exposure to liver microsome fractions, 
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regardless of NADPH presence. Both N-terminal and C-terminal degraded products of 
L(KLAKLAK)2 were found at 10 min, 30 min, and 60 min, and their identity was 
verified by MS-MS profile.  At 24 hours, some degraded products were still detected in 
the samples with microsomes, but without NADPH. However, in the presence of 
NADPH, degradation products were absent. The fact that there was no significant 
difference between samples with and without NADPH, indicates that the degradation is 
likely the result from metabolism from enzymes other than CYP450.  
 
D(KLAKLAK)2 peptido-mimetic exhibits Gram-negative bactericidal activity 
 We determined the spectrum of D(KLAKLAK)2 activity against a variety of 
bacteria and mold species using the broth dilution method published by the Clinical and 
Laboratory Standards Institute (CLSI) in the USA (CLSI document M100-S16CLSI), 
and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) in 
Europe (310).  Table 3-1 summarizes the D(KLAKLAK)2 minimum inhibitory 
concentration (MIC) measured for each strain tested. These data suggest that 
D(KLAKLAK)2 is effective against Gram-negative bacteria such as P. aeruginosa, A. 
baumannii, K. pneumoniae and E. coli.  Molds such as Rhizopus oryzaye and Mucor sp. 
and yeasts such as Candida sp. and the fungus Cryptococcus albidus were also found to 
be sensitive to treatment with D(KLAKLAK)2. However, in this study, we investigated 
only D(KLAKLAK)2 activity against Gram-negative bacteria.  
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Figure 3-1.  
D
(KLAKLAK)
2
 is resistant to degradation by human liver 
microsomes.  Intact 
D
(KLAKLAK)
2
 was detected 0, 10, 30, 60 minutes and 24 
hours after continuous exposure to microsomal enzymes in the presence 
(blue line) and absence of NADPH (green line).  
L
(KLAKLAK)
2
 concentrations 
decreased rapidly over time with complete degradation observed within 24 hours 
of exposure to liver microsome fractions both in the presence (black line) and 
absence (red line) of NADPH.
  57 
 
 
 
 
 
1150 1320 1490 1660 1830 2000
1692.8
0
++
+
+
D
(K
L
A
K
L
A
K
) 2
+
13
C
-(
K
L
A
K
L
A
K
) 2
+
D
(K
L
A
K
L
A
K
) 2
+
K
+
13
C
-(
K
L
A
K
L
A
K
) 2
+
K
+
D
(K
L
A
K
L
A
K
) 2
+
2K
+
13
C
-(
K
L
A
K
L
A
K
) 2
+
2K
+
P
er
ce
n
t 
in
te
n
si
ty
 (
%
)
Mass (m/z)
D
(K
L
A
K
L
A
K
) 2
+
13
C
-(
K
L
A
K
L
A
K
) 2
+
D
(K
L
A
K
L
A
K
) 2
+
K
+
13
C
-(
K
L
A
K
L
A
K
) 2
+
K
+
D
(K
L
A
K
L
A
K
) 2
+
2K
+
13
C
-(
K
L
A
K
L
A
K
) 2
+
2K
+
D
(K
L
A
K
L
A
K
) 2
+
13
C
-(
K
L
A
K
L
A
K
) 2
+
D
(K
L
A
K
L
A
K
) 2
+
K
+
13
C
-(
K
L
A
K
L
A
K
) 2
+
K
+
D
(K
L
A
K
L
A
K
) 2
+
2K
+
13
C
-(
K
L
A
K
L
A
K
) 2
+
2K
+
D
(K
L
A
K
L
A
K
) 2
+
13
C
-(
K
L
A
K
L
A
K
) 2
+
D
(K
L
A
K
L
A
K
) 2
+
K
+
13
C
-(
K
L
A
K
L
A
K
) 2
+
K
+
D
(K
L
A
K
L
A
K
) 2
+
2K
+
13
C
-(
K
L
A
K
L
A
K
) 2
+
2K
+
D
(KLAKLAK)
2
+microsomes+NADPH
t=60 minutes
D
(KLAKLAK)
2
+microsomes
t=60 minutes
D
(KLAKLAK)
2
t=60 minutes
D
(KLAKLAK)
2
t=0
3255.6
3082.4
13000
100
50
1150 1320 1490 1660 1830 2000
0
P
er
ce
n
t 
in
te
n
si
ty
 (
%
)
Mass (m/z)
100
50
1150 1320 1490 1660 1830 2000
0
P
er
ce
n
t 
in
te
n
si
ty
 (
%
)
Mass (m/z)
100
50
1150 1320 1490 1660 1830 2000
0
P
er
ce
n
t 
in
te
n
si
ty
 (
%
)
Mass (m/z)
100
50
Figure 3-2.  
D
(KLAKLAK)
2
 is resistant to degradation by human liver microsomes. 
No degradation products of 
D
(KLAKLAK)
2
 were found for up to 24 hours post 
continuous exposure to microsomal enzymes. Representative mass spectra are shown at 
(A) pre-incubation; (B) 60 minutes in buffer at 37oC; (C) 60 minutes post incubation with 
pooled human liver microsomes and (D) 60 minutes post incubation with pooled human 
liver microsomes in the presence of NADPH.
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Figure 3-3.  
L
(KLAKLAK)
2
 is rapidly degraded during exposure to human liver 
microsomes.  Degradation products resulting from both N-terminal and C-terminal 
proteolysis of 
L
(KLAKLAK)
2
 were found at 10 min, 30 min, and 60 min.  
Representative mass spectra are shown at (A) pre-incubation; (B) 60 minutes in 
buffer at 37oC; (C) 60 minutes post incubation with pooled human liver microsomes 
and (D) 60 minutes post incubation with pooled human liver microsomes in the 
presence of NADPH.
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Table 1.  MIC values for selected organisms tested for D(KLAKLAK)2 susceptibility. 
Organism MIC µg/ml 
D(KLAKLAK)2 
Acinetobacter baumannii ATCC 19606 300 
Pseudomonas aeruginosa (PAO1) 75 
Pseudomonas aeruginosa (PA14) 75 
Escherichia coli ATCC 25922 150 
Klebsiella pneumoniae 300 
Stenotrophomonas maltophelia 300 
Cryptococcus albidus 150 
Candida albicans 300 
Staphylococcus aureus Not effective 
Staphylococcus epidermidis Not effective 
Mucor sp. 300 
Rhizopus oryzaye 300 
Aspergillus fumigatus Not effective 
Fusarium oxysporum Not effective 
Fusarium solani Not effective 
Scedosporium prolificans Not effective 
Aspergillus terreus Not effective 
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Gram-negative bacterial growth is inhibited within 4 hours after exposure to 
D(KLAKLAK)2 
 Although wildly used to determine antibiotic efficacy, MIC measurements do not 
provide information about the dynamic interaction between the drug and bacteria. To 
begin to understand the kinetics of this interaction, we compared time-kill curves of four 
different strains at multiples of MIC for a period of 24 hours. D(KLAKLAK)2 treatment 
induced significant bacterial growth inhibition ranging between two to four logs, 
beginning at 4 hours after exposure. The effect of D(KLAKLAK)2  peptido-mimetic was 
specific and dose- and time-dependent. However, substantially distinct killing rates were 
observed among species (Fig. 3-4). 
 Considering the potential therapeutic use of this peptide, we next examined 
whether D(KLAKLAK)2 exerts bactericidal activity against clinical isolates and if its 
activity correlates with already acquired antibiotic resistance. We determined the MIC of 
89 strains of P. aeruginosa, K. pneumoniae, and E. coli, respectively.  Susceptibility 
profiles indicated that the average MIC extends from 150 µg/ml for E. coli  and P. 
aeruginosa to 600 µg/ml for K. pneumoniae, respectively (Fig. 3-5).  Comparative 
analysis of routinely tested antibiotics susceptibility profiles (Table 3-2) and 
D(KLAKLAK)2 effect revealed no correlation between MDR and peptide susceptibility. 
For instance, five E. coli clinical isolates are sensitive to all antibiotics tested, yet they 
display average sensitivity to D(KLAKLAK)2 (150 µg/ml). Similarly, one E. coli clinical 
isolate found to be resistant to most antibiotics tested, also exhibits average sensitivity to 
D(KLAKLAK)2 (150 µg/ml). Among the twenty-five P. aeruginosa strains tested, four 
were resistant to 5 to 8 antibiotics. However, these strains exhibited different  
  61 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Figure 3-5. 
D
(KLAKLAK)
2
 exerts bactericidal activity against clinical 
isolates.  MIC of clinical strains of E. coli (A), K. pneumoniae (B), and 
P. aeruginosa (C) represented in µg/ml.
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Table 2.  Clinical isolates resistance profiles.  Red highlight indicates isolates 
specifically mentioned in the text. 
 
 Number of E. coli Isolates Resistant to Routinely Tested Antibiotics 
D(KLAKLAK)2 
MIC µg/ml 
0 1-4 5-8 9-12 13-16 
37 0 3 0 0 0 
150 5 9 2 1 0 
300 3 4 1 0 0 
 Number of P. aeruginosa Isolates Resistant to Routinely Tested 
Antibiotics 
D(KLAKLAK)2 
MIC µg/ml 
0 1-4 5-8 9-11 13-14 
37 2 0 0 1 0 
150 2 4 3 0 0 
1200 1 0 1 0 0 
 Number of K. pneumoniae Isolates Resistant to Routinely Tested 
Antibiotics 
D(KLAKLAK)2 
MIC µg/ml 
0 1-4 5-8 9-12 13-14 
75 0 0 0 0 1 
600 0 10 0 0 0 
1200 0 5 0 0 0 
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susceptibilities to D(KLAKLAK)2, spanning from the lowest to the second highest 
concentration tested. The most striking example is represented by a K. pneumoniae 
clinical isolate found to be resistant to all antibiotics tested, yet highly sensitive to 
D(KLAKLAK)2 (75 µg/ml)..  
 Combination therapy has been shown to enhance antibiotic effectiveness and to 
contribute less frequently than monotherapy to selection of resistance. We hypothesized 
that D(KLAKLAK)2 may have synergistic activity with different classes of antibiotics. 
As an example, we performed an in vitro time-kill assays to determine the activity of 
D(KLAKLAK)2 in combination with piperacillin. Our results indicated a significant 
synergistic effect within 4 hours after treatment at one half time the MIC for both 
peptide and the conventional antibiotic piperacillin (Fig. 3-6).  
 
D(KLAKLAK)2 activity is growth type and stage independent 
 Antibiotic susceptibility is routinely tested on planktonic microorganisms during 
exponential growth phase. However, certain types of infections are caused by bacteria 
growing as a biofilm. Adherent growth renders microorganisms 100 to 1000 times less 
affected by antibiotics. To determine whether D(KLAKLAK)2 is active against bacterial 
biofilms, we exposed a 24 hour old P. aeruginosa biofilm to increasing concentrations of 
peptide. Similar to regular use antibiotics, D(KLAKLAK)2 was less effective against P. 
aeruginosa biofilm (400 µg/ml) compared to free-growing cells (150 µg/ml). Notably, 
the increase in susceptibility is less than 3 times suggesting that the peptide diffuses 
efficiently through the biofilm and it is active against the metabolically active cells 
present at the outer surface of the biofilm as well as the slow growing bacteria present in  
  65 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Figure 3-6. Synergistic effect of 
D
(KLAKLAK)
2
 and piperacillin.  Time-killing 
curve showed that a combination of 1/2 MIC of 
D
(KLAKLAK)
2
 with 1/2 MIC piperacillin 
(red line) significantly enhanced the bactericidal effect when compared 
to the activity of each drug alone: piperacillin, black line and 
D
(KLAKLAK)
2
 blue line.
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the inner layers. Moreover, the activity of D(KLAKLAK)2 was found to be similar in 
cation-adjusted Muller-Hinton and 10% fetal bovine serum RPMI suggesting that the 
effects of D(KLAKLAK)2 are not media dependant (Fig. 3-7). 
We subsequently reasoned that D(KLAKLAK)2 might also be active against 
stationary growth phase bacteria. The ability of peptide to kill bacteria was measured 
using the LIVE/DEAD BacLight kit.  This assay employs a combination of two nucleic 
acid stains used to distinguish live bacteria with an intact membrane from dead bacteria. 
Live cells stained green with SYTO9 while dead bacteria stained red and yellow due to 
SYTO9 and propidium iodide.   
Unlike most conventional antibiotics that are active only against metabolically 
active cells, the peptide equally affected exponential and stationary growth phase P. 
aeruginosa (Fig. 3-8). 
 
D(KLAKLAK)2 causes morphological membrane damage 
 In considering the amphipathic peptide mode of action, we first hypothesized that 
the peptide might induce gross bacterial membrane damage. Electron micrographs of P. 
aeruginosa incubated with freshly prepared D(KLAKLAK)2 at increasing concentrations 
revealed clear morphologic evidence of membrane damage (Fig. 3-9).  
 To elucidate the underlying mechanism of action, we employed the lysozyme 
lysis assay to determine outer membrane loss of integrity. When the bacterial membrane 
is damaged, lysozyme gains faster access to its peptidoglycan substrate inducing rapid 
cell lysis. A. baumannii 19606 and P. aeruginosa were exposed to increasing 
concentrations of D(KLAKLAK)2 in the presence of lysozyme. The synthetic peptide  
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Figure 3-7.  
D
(KLAKLAK)
2
 inhibits biofilm growth.  Twenty-
four hour-old biofilm grown in LB (A) or 10% FBS RPMI (B)
was treated wtih increasing concentrations of 
D
(KLAKLAK)
2.
Both visual (A,B) and quantative (C) assesment demonstrated
dose-dependant eradication of biofilm.
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facilitated rapid lysozyme-induced cell lysis in a concentration dependant manner. P. 
aeruginosa was completely lysed when exposed to16 µg/ml of peptide while only 60% 
of the A. baumannii cells were destroyed at the same concentration. In contrast, a control 
peptide had no effect on the bacterial membrane (Fig. 3-10). Since the MICs for A. 
baumannii 19606 and P. aeruginosa are similar, genus-specificity suggests the 
possibility that the peptide activity is time dependent. 
Severe membrane injury usually results in membrane potential dissipation and 
cell death due to loss of membrane function. We next sought to assess whether the loss 
of membrane integrity results in membrane depolarization using the membrane 
potential-sensitive dye diSC3(5). Bacterial exposure to D(KLAKLAK)2 induced  a dose 
dependant loss of membrane potential in all strains tested. However, a control peptide 
had no effect on the bacterial membrane suggesting that D(KLAKLAK)2 activity is 
specific (Fig. 3-11).   
 
D(KLAKLAK)2 exerts its effect on membrane lipids  
 We next sought physical evidence of interaction between the peptide and cell 
membrane lipids. Giant unilamellar vesicles derived from E. coli extract devoid of 
membrane proteins were treated with 3 µg of D(KLAKLAK)2. Upon exposure to the 
peptide, the liposomal membrane appeared punctuated suggesting lipid dissolution 
perhaps as a result of D(KLAKLAK)2 insertion into the lipid bilayer (Fig. 3-12).  This 
effect was not seen with a control peptide (data not shown).   
 To further demonstrate lipid membrane dissolution, we investigated the ability of 
D(KLAKLAK)2 to disrupt dual labeled liposomes using fluorescence resonance energy  
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 causes dose dependant membrane 
permeability. 
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 induces membrane permeability in 
PAO1, PA14, and A. baumannii 19606 (A, B, C black lines, 
respectively).  A control peptide (blue line) did not affect the membrane.
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Figure 3-11. 
D
(KLAKLAK)
2
 treatment induces dose dependant loss 
of membrane potential. 
D
(KLAKLAK)
2
 causes loss of membrane 
potential in PAO1, PA14, and A. baumannii 19606 (A, B, C black lines,
respectively) when compared with a control peptide (blue line).  
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Figure 3-12.  
D
(KLAKLAK)
2 
exerts its effect on lipid bilayers devoid of membrane 
proteins.  Giant unilamellar vesicles derived from E. coli extract devoid of membrane proteins 
treated with 3 !g of 
D
(KLAKLAK)
2
 (bottom row) showed clear punctate staining, evidence of 
lipid membrane dissolution when compared to vehicle alone (top row).  
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transfer (FRET). E. coli extract-derived liposomes labeled with either Nitro-2-1,3-
BenzoxaDiazol-4-yl (NBD) phosphatidylethanolamine (PE) (excitation at 460 nm and 
emission at 534 nm), or rhodamine PE (excitation at 550 nm and emission at 590 nm), 
were incubated with increasing concentrations of D(KLAKLAK)2. When the liposomes 
are intact, the two fluorescent lipids are not in close enough proximity to yield an 
efficient energy transfer.  However, when D(KLAKLAK)2 disrupts the liposomal 
membrane, free lipids are able to come in close contact leading to FRET.  Energy 
transfer causes a decrease in emission intensity at 534 nm (NBD emission) and a 
corresponding increase in the emission intensity at 590 nm (rhodamine emission). In 
support of our hypothesis, D(KLAKLAK)2 disrupted the integrity of liposomes indicated 
by the  emergence of an emission peak at 590 nm with the corresponding reduction of 
the peak at 534 nm.  A control peptide had no influence on liposome integrity whereas 
ethanol disrupted both type of liposomes resulting in an energy transfer similar with the 
one induced by D(KLAKLAK)2 (Fig. 3-13). 
 
D(KLAKLAK)2 specifically disrupts bacterial membrane  
 Because the bacterial outer layer and eukaryotic membrane lipid composition are 
different, we next asked whether D(KLAKLAK)2 interacts only with lipids specific for 
the microbial outer layer. Phosphatidylethanolamine (PE), phosphatidylglycerol (PG) 
and phosphatidylserine (PS) represent the most common bacterial lipids; whereas the 
eukaryotic cell membrane has a more sophisticated composition with 
phosphatidylcholine (PC) (24%) and cholesterol (17%) as major components. E. coli 
extract-derived labeled liposomes supplemented with increasing concentrations of each  
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Figure 3-13. 
D
(KLAKLAK)
2 
disrupted the integrity of liposomes.  
D
(KLAKLAK)
2 
 disrupted the integrity of labeled E. coli extract derived liposomes  
as indicated by the  emergence of an emission peak at 590 nm with the 
corresponding reduction of the peak at 534 nm.  A control peptide had no 
influence on liposome integrity whereas ethanol disrupted the liposomes 
resulting in an energy transfer similar with the one induced by 
D
(KLAKLAK)
2 
.
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specific lipids were incubated with D(KLAKLAK)2 and assessed for FRET. Consistently, 
PE, PG and PS increased the susceptibility of liposomes to D(KLAKLAK)2 in a dose 
dependent manner as demonstrated by a decrease in the peak at 534 nm complemented 
by an increase in the peak at 590 nm (Fig. 3-14, A, B, C). As expected, the addition of 
PC and cholesterol decreased the susceptibility of the E. coli extract liposomes to the 
peptide (Fig 3-14 D, Fig. 3-15).  
 To further demonstrate that D(KLAKLAK)2 does not disrupt the eukaryotic 
membrane, we tested erythrocyte hemolysis after treatment with increasing 
concentrations of D(KLAKLAK)2. Hemolysis was assessed at 1, 3, and 48 hours of 
exposure by measuring the absorbance hemoglobin release in the supernate at 415 nm. 
In support of our hypothesis, the peptide had no hemolytic activity even after 48 hours of 
treatment (Fig. 3-16). 
 Taken together, this data demonstrates that D(KLAKLAK)2 causes outer 
membrane bilayer dissolution, which results in dissipation of membrane potential and 
bacterial death. Moreover, the peptide acts specifically on the bacterial membrane 
without disrupting the eukaryotic cell homeostasis.  
  77 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Figure 3-15. The effect of 
D
(KLAKLAK)
2
 on the lipid bilayer was 
significantly blunted with the addition of cholesterol to the liposomal 
membrane.  Cholesterol decreased the susceptibility of the E. coli extract 
derived liposomes to the 
D
(KLAKLAK)
2
 treatment in adose dependant manner 
as shown with a increase in the peak at 534 nm and adrop in the peak at
590 nm.  
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Figure 3-16.  
D
(KLAKLAK)
2  
does not cause erythrocyte hemolysis.  
Hemolysis of erythrocytes was measured via absorbance at 415 nm 
48 hours after treatment with 
D
(KLAKLAK)
2 
.  The effect of 
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2 
 treatment was insignificant when compared to the vehicle
(negative control) or Triton X-100 (positive control). 
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Introduction 
 Enterococci are capable of causing a variety of potentially life-threatening 
infections and, in the USA, are ranked as the second most common cause of nosocomial 
infections after staphylococci (311). The current treatment of enterococcal infections has 
become an enormous challenge for clinicians due to the fact that this organism 
frequently exhibits multidrug resistance to the standard drugs of choice, namely 
ampicillin, aminoglycosides (high-level resistance) and vancomycin.  Moreover, there 
has been a striking increase in the frequency of isolation and spread of VRE in hospitals 
around the world which significantly increase mortality, hospital stay and/or 
hospitalization costs (312). Enterococcus faecium is one of the “E’s” in the so-called 
ESKAPE pathogens, highlighted by the Infectious Diseases Society of America as 
problem pathogens requiring new therapies (313). Only two compounds are currently 
FDA-approved for the treatment of VRE infections, linezolid and quinupristin-
dalfopristin. Both have important limitations for the treatment of severe VRE infections 
due to the frequent occurrence of clinical failures and recurrences, adverse toxicity 
profile, limited spectrum, bacteriostatic effect against VRE and increased reports of 
resistance. DAP is a lipopeptide antibiotic with in vitro bactericidal activity against 
enterococci which was approved in 2003 for the treatment of skin and soft tissue 
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infections (including for vancomycin-susceptible E. faecalis) and, in 2006, for the 
treatment of bacteremia and right-sided infective endocarditis caused by Staphylococcus 
aureus.  Even though DAP does not have an indication for the treatment of VRE 
infections, it has in vitro bactericidal activity against enterococci (including ampicillin-
resistant and VRE) and clinicians often use this compound off-label in severe 
enterococcal infections due to the lack of reliable options (314).  A major drawback to 
the use of DAP for the treatment of VRE infections is the development of resistance 
during therapy (301, 315, 316). Although little is known about the mechanism of DAP 
resistance in enterococci, a critical step in DAP action is its interaction with the bacterial 
CM in a calcium-dependent manner.   
 Previous studies in S. aureus indicate that the development of DAP resistance is 
associated with important changes in the composition and function of the CM, cell 
envelope and, in some cases, CW (317).  It has been shown that there are multifactoral 
pathways associated with DAP resistance in S. aureus and these pathways differ among 
resistant strains (317, 251, 318).    In a recent study by Jones et al., using isogenic sets of 
S. aureus clinical isolates from a DAP-treated patient, a variety of CM and cell envelope 
alterations involving membrane fluidity, membrane phospholipid composition and 
asymmetry, and surface charge were found to be associated with the DAP-resistant 
phenotype (317).  In addition to the phenotypic changes that have been described, there 
are many examples of alterations in the CW function and structure that have been 
proposed.  In studies by Cui et al. (319) and Julian et al. (320) thickening in the CW was 
described suggestive of a physical barrier to DAP reaching the CM.  Also, it has been 
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reported (321) that DAP-resistant S. aureus strains exhibit both (i) reduced membrane 
depolarization, and (ii) reduced daptomycin binding to the cytoplasmic membranes.  
 In addition to the phenotypic changes observed in DAP resistant S. aureus 
strains, genetic changes have also been identified.  It has been found that mutations in 
the genes mprF, yycG, rpoB and rpoC are induced by in vitro passages in sub-inhibitory 
concentrations of DAP.  These genetic mutations lead to changes in membrane charge 
through lysinylation of PG (322) alteration of membrane fatty acid biosynthesis, and 
changes in RNA polymerase, respectively.   
 Here we describe characterization of the CW and CM of a clinical pair of VRE 
E. faecalis isolates obtained from the blood of a patient with fatal bacteremia before 
(DAP-susceptible) and after (DAP-resistant) DAP therapy (DAP minimal inhibitory 
concentrations of 1 and 16 µg/ml, respectively). Our findings indicate that, similar to S. 
aureus, development of DAP-resistance in a vancomycin-resistant E. faecalis isolate is 
associated with alterations of the CW and properties of the CM. However, the genes 
linked to these changes in enterococci appear to be different from those described in S. 
aureus.  
 
 
Results 
Development of DAP resistance is associated with marked ultrastructural changes  
 TEM revealed important differences in the cell morphology of the two isolates. 
DAP-resistant cells tended to clump and formed aggregates with longer chains than 
DAP-susceptible cells. At higher magnifications, the presence of multiple septal 
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structures before complete cell separation was evident in the DAP-resistant cells (Fig. 4-
1).  The number of cells with a septum was consistently higher in the DAP-resistant 
isolate compared to the DAP-susceptible isolate (P<0.05) (Fig. 4-2). Additionally, the 
CW thickness of the DAP-resistant isolate was greater than that of the DAP-susceptible 
isolate  (average 18.12 + 2.23 and 10.43 nm + 1.34, respectively, p<0.05) (Fig. 4-3).  
 
Alterations of CM potential are associated with the development of DAP-resistance  
 After determining that ultrastructural changes were present in the resistant E. 
faecalis isolate, we furthered our analysis of the cell membrane to determine if 
differences existed in DAP induced cell membrane potential loss.  DAP dissipated the 
CM potential in a concentration-dependent manner after 5 min of exposure in DAP-
susceptible cells. Conversely, this effect was significantly blunted in the DAP-resistant 
isolate (Fig. 4-4), indicating that emergence of DAP-resistance was associated with 
alterations in the ability to depolarize the target CM.  
 
DAP-resistance is related to changes in DAP-induced permeability. 
Using the LIVE/DEAD BacLight Kit, the DAP-susceptible isolate was shown to 
undergo a concentration-dependent increase in permeabilization after 5 min of DAP 
exposure. Conversely, the DAP-resistant isolate showed striking reductions of DAP-
induced CM permeabilization (Fig. 4-5). This effect was seen at different time points 
from 10 min to 60 min.    
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DAP susceptible     DAP resistant
Figure 4-1.  Ultrastructural changes of DAP-resistant isolate compared to 
DAP-susceptible parental strain.  Electron micrographs revealed surface 
structures present on DAP-resistant (B) individual cells or connecting between 
cells not observed in the DAP-susceptible isolate (A).  
A B
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Figure 4-4.  DAP-resistant isolate is less susceptible to DAP-induced membrane 
permeabilization.  The DAP-resistant (open bars) isolate was less susceptible to 
DAP-induced membrane permeabilization when compared to the DAP-susceptible
(filled bars) strain.  The difference in susceptibility was seen as early as 10 
minutes (A) after treatment with DAP at concentrations up to 60 µg/ml (5X the 
MIC of the DAP-resistant isolate).  This trend continued at measurements made 
20, 30, 60 and 90 minutes (B, C, D, E, respectively) after treatment.  
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Surface charge differences between DAP-resistant and DAP-sensitive E. faecialis 
isolates. 
The overall surface charge in the DAP-resistant and DAP-sensitive isolates was 
investigated using the cationic cytochrome c molecule.  Increased cell surface charge in 
DAP-resistance in S. aureus is well documented, and the surface charge appears to play 
an important role in the interaction of the antibiotic with the CM. It has been postulated 
that a more positively charged cell envelope can presumably “repel” cationic AMPs 
including DAP away from the CM and contribute to the development of resistance 
(317).  DAP-resistant cells had significantly higher amount of unbound cytochrome c, 
indicating a more positively charged surface vs. the DAP-susceptible cells (P<0.05) (Fig 
4-6).   
Collectively, our results suggest that development of DAP-resistance in vivo in E. 
faecalis is associated with profound ultrastructural changes in the CM, septal apparatus 
and CW surface charge, DAP-induced membrane permeabilization and potential loss.  
Taken together, all of these alterations likely enhance the organism’s ability to resist CM 
damage caused by the positively charged calcium-associated DAP.  
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DAP-resistant DAP-susceptible
0.06
0.04
0.02
0
Figure 4-6.  DAP-resistant cell surface 
more positivley charged.  DAP-resistant
cells had significantly higher amount of 
unbound cytochrome c, indicating a more 
positively charged surface in comparison 
to the DAP-susceptible cells (p<0.05).  
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Although numerous organizations, independent clinicians and scientists 
have alluded to the danger posed by the tremendous increase of infections caused 
by MDR bacteria, the research and development of new antibiotics is lagging far 
behind the ability of microorganisms to become resistant to current therapies 
(323, 324).  Recent reports focused on the identification of agents being 
developed have shown that the number of antimicrobials in clinical trials is very 
low and that most of these compounds are active against Gram-positive 
pathogens (325, 313).  These studies emphasize the danger posed by MDR 
Gram-negative bacteria since none of the therapies in development display a new 
mode of action (313, 325).  The results reported here propose that severe outer 
membrane injury may represent a platform for novel drug development against 
Gram-negative bacteria.  
Amphipathic AMPs have been previously shown to cause bacterial death 
via membrane disruption, but the therapeutic promise is hindered by their 
susceptibility to degradation, potential toxicity and high synthesis costs (326).  A 
synthetic peptide, L(KLAKLAK)2, revealed high bactericidal activity combined 
with insignificant eukaryotic cell toxicity (289).  Here we show that not only the 
all D-enantiomer of the (KLAKLAK)2 peptide retains its antimicrobial activity 
against Gram-negative bacteria but is also resistant to degradation by the 
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CYP450 enzyme. We speculate that the ability to withstand proteolysis may 
allow lower therapeutic doses, longer availability and improved cost efficiency.  
Despite the constant use of MIC to determine antimicrobial susceptibility 
and guide treatment, this method does not provide any insight into the 
equilibrium of the bacteria-drug interaction. Moreover, the MIC provides 
information exclusively about the susceptibility of free, actively growing 
organisms. The sensitivity of quiescent, slow growing bacteria or biofilms to 
antimicrobials remains unknown, and differs from the susceptibility of 
exponential phase organisms.  Therefore, a large number of infections receive 
sub-inhibitory drug concentrations, potentially contributing to emergence of drug 
resistance. The in vitro dynamic interaction of D(KLAKLAK)2  with several 
bacterial species showed that the number of bacteria decreases by two to four 
logs within 4 hours of treatment. Two commonly used P. aeruginosa strains, 
PAO1 and PA14, revealed different growth inhibition profiles. At MIC, PAO1 
growth abruptly decreased within 4 hours, however, by 10 hours the rate of 
multiplication exceeded the peptide-induced killing rate. At concentrations 
higher than the MIC, we observed dose- and time-dependent growth inhibition. 
In contrast, PA14 was less sensitive to D(KLAKLAK)2. Although the growth 
inhibition of PA14 was initially dose dependent, after 24 hours the overall 
peptide activity was not significant. In the case of A. baumannii 19606 and E. 
coli 25922, D(KLAKLAK)2 induced dose- and time-dependent growth inhibition 
with cidal effect at all concentration after 10 hours and 24 hours, respectively. 
The differences in susceptibility to D(KLAKLAK)2  may be attributed to several 
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factors: i) species- specificity, ii) already acquired resistance to antimicrobials, 
iii) growth conditions or iv) secretion of factors that may interfere with peptide 
activity. Most likely growth conditions play an important role. As mentioned 
before, MIC testing is performed under static conditions, whereas time-kill 
curves involve culture aeration that may greatly affect the growth rate. Another 
possibility is that drug sensitivity is altered by the type or stage of growth. In 
fact, our data indicated that the peptide is able to dismantle 24-hour-old biofilm 
grown on plastic plates. This raised the possibility that D(KLAKLAK)2 is active 
not only against growing bacteria but also against quiescent cells or stationary 
phase bacteria. Notably, live-dead microscopy assays indicated that the peptide is 
active regardless of the growth stage. This observation is of crucial importance in 
the context of persistent infections. Most commonly used antibiotics interfere 
with protein, RNA, DNA, peptidoglycan and folic acid synthesis processes that 
are active only in growing bacteria (327).  In contrast, persistent infections are 
caused by dormant or slow-growing organisms such those within biofilms. These 
infections are hardly eliminated by commonly used antibiotics and therefore 
more susceptible to acquiring resistance to antimicrobials.  
To further distinguish the factors that influence D(KLAKLAK)2 activity, 
we tested approximately 100 clinical isolates with different antibiotic 
susceptibilities. Our data indicated a lack of correlation between already acquired 
antimicrobial resistance and susceptibility to D(KLAKLAK)2. Furthermore, 
combination therapy using piperacillin and D(KLAKLAK)2, both at one half MIC, 
indicate a synergistic effect.  
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The mechanism of amphipathic AMPs action has been fairly well 
defined. Bacterial death occurs as a result of membrane permeabilization caused 
by peptide insertion into the lipid bilayer (268).  Electron microscopy studies 
demonstrated membrane damage and formation of membrane blebs. Depending 
on the agents used, cell death and membrane deterioration occur at the same time 
or the membrane injury continues long after loss of cell viability.  Similarly, we 
observed ultrastructural membrane damage starting at treatment with 37.5 µg/ml 
D(KLAKLAK)2 and more obvious at 150 µg/ml peptide after 25 minutes of 
treatment. Using the lysozyme lysis assay, we showed that D(KLAKLAK)2 
induced a loss of membrane integrity as measured by the ability of the peptide to 
increase lysozyme access to its peptidoglycan substrate and induce cell lysis. 
Surprisingly, amounts as low as 20 µg/ml D(KLAKLAK)2 created membrane 
pores large enough to allow complete cell lysis suggesting that the actual lipid 
bilayer damage is more intense than the modification observed in our electron 
micrographs.  
As noted previously, bacterial membranes serve not only structural 
functions, but also support selective transport and energy storage (328).  
Membrane destabilization promotes loss of membrane potential, ultimately 
resulting in cell death. As shown by our results, D(KLAKLAK)2 treatment 
induced dose-dependent membrane depolarization correlated with bacteria loss 
of viability. 
As shown by our model membrane assays, D(KLAKLAK)2 interacts 
solely with lipids specifically found in the bacterial membrane and this 
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interaction is inhibited by the addition of PC or cholesterol, components 
predominantly present in the eukaryotic membrane. Targeted activity allows the 
peptide to neutralize bacteria without perturbing the eukaryotic membrane. 
Indeed, concentrations of bactericidal concentrations of D(KLAKLAK)2 had no 
hemolytic activity. In agreement, we previously showed that untargeted peptide 
could not induce apoptosis of KS1767 or MDA-MB-435 cells (309). 
Taken together, our in vitro susceptibility and mechanistic studies suggest 
that (KLAKLAK)2 maintains its activity against Gram-negative bacteria in the 
all-D proteolytically stable form. Natural and synthetic AMPs have been 
previously proposed as an alternative to antibiotics because their selective 
activity against microbes and lack of ability to quickly induce resistance (329). 
However, their high synthesis cost, instability, bioavailability and high sensitivity 
to salt and serum, and occasional toxicity have been considered hindering 
features for drug development (275). Although far from being ready for clinical 
applications, we speculate that a stable peptide may allow higher bioavailability, 
eliminate instability and improve cost-efficiency by using lower amounts of drug 
for treatment. In addition, our data indicated that the peptide activity is not 
influenced by either high salt or serum presence. Moreover, work performed in 
our laboratory exploiting the pro-apoptotic D(KLAKLAK)2 capability revealed 
fairly low toxicity at therapeutic concentrations. However, we acknowledge that 
the toxicology profiles for cancer and infection may differ. Notably, the peptide 
alone or in combination with commonly used antibiotics is also active against 
persistent infections such as biofilms and MDR clinical isolates. In the event that 
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the peptide displays high toxicity at the concentrations necessary to eliminate 
infection in vivo, we propose that we could at least exploit this agent for 
combination therapy, as coating component for biomedical devices or as topical 
antibiotic.  
In summary, we believe that the D(KLAKLAK)2 mode of action may 
represent a stepping-stone for the development or improvement of drugs with 
broad activity against the lipid bilayer. On this note, a D(KLAKLAK)2 variant 
with improved pro-apoptotic activity has already been reported (330).  Therefore, 
our future experiments will focus on the engineering of divergent peptides with 
improved antibacterial activity, defining the peptide activity to eliminate 
infection in vivo, delineate its toxicological and pharmacokinetics profiles.  
As previously stated, it is considered that development of resistance does 
not represent an obstacle for AMPs clinical development.  In 2003, the FDA 
approved the lipopeptide antibiotic DAP.  DAP is not, in its native form, a 
traditional AMP.  However DAP renders itself a de-novo AMP in the presence of 
calcium ions.  DAP is proposed to cause bacterial cell death in the same manner 
as traditional AMPs. It is widely accepted that DAP first binds to the Gram-
positive bacterial membrane followed by rapid depolarization resulting in a loss 
of membrane potential which leads to protein, DNA and RNA synthesis 
inhibition, resulting in bacterial cell death.  
Recently, Gram-positive strains with decreased susceptibility to DAP 
have been reported, yet the mechanism of resistance in enterococci remains 
unknown. Our findings indicated that, similar to S. aureus, development of DAP-
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resistance in a vancomycin-resistant E. faecalis isolate is associated with 
alterations of the CW and CM properties. However, the genes linked to these 
changes in enterococci appear to be different from those described in S. aureus.  
The treatment of modern-day enterococcal infections has become a major 
challenge since there is a lack of reliable options to treat ampicillin-resistant 
VRE infections. The off-label use of DAP is often employed in the treatment of 
severe enterococcal infections including VRE or those exhibiting high-level 
resistance to aminoglycosides. However, a major drawback for the successful use 
of this antibiotic is the emergence of resistance during DAP therapy. Moreover, 
enterococci are less susceptible in vitro to DAP than S. aureus with a breakpoint 
four-fold higher than for S. aureus (< 4 µg/ml vs < 1 µg/ml, respectively) (CLSI 
document m100-s20). Thus, an understanding of the molecular events that lead to 
the development of DAP-resistance is of vital importance when designing new 
therapeutic strategies for salvaging the use of DAP against VRE (e.g., higher 
dose schemes or combination therapies) and has the potential to identify or 
validate new targets for the development of novel antimicrobial agents against 
these organisms.  
An essential event for the activity of DAP is the calcium-mediated 
interaction of this antibiotic with the CM. The interaction of DAP with the CM of 
enterococci is not as well defined as the interaction of antimicrobial peptides 
with Gram-negative bacteria.  Gram-positive cells have a thick layer of 
peptidoglycan that the antimicrobial peptide molecule must transverse to reach 
the target site of action.  Therefore, modifications to this barrier that make the 
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peptide less able to interact with the membrane would reduce the effectiveness of 
the peptide.  We identified marked distortions of the CW, surface and septal 
apparatus in the DAP-resistant isolate in our clinical strain pair set. Some of the 
cell surface changes (e.g., cell surface protrusions) have not been previously 
described with DAP resistance. These changes suggest that emergence of 
resistance to DAP in enterococci during therapy is also related to important 
alterations of CW homeostasis. Indeed, previous studies in S. aureus indicate that 
inhibition of peptidoglycan biosynthesis and activation of the CW stress response 
is involved in DAP action and non-susceptibility (331). 
In addition, the surface charge appears to play an important role in the 
interaction of the antibiotic with the CM and it has been postulated that a more 
positively charged cell envelope can presumably “repel’ cationic AMPs, 
including DAP, away from the CM and contribute to the development of 
resistance (317).  A major contributor of the cell surface charge is the 
phospholipid composition of the inner and outer CM leaflets, such as the 
negatively charged cardiolipin (CL) and positively-charged amino derivatives of 
PG. In some S. aureus isolates, reduced susceptibility to DAP has been attributed 
to a decrease in the overall cell surface charge as a result of modifications in 
phospholipid content, mainly through an increased synthesis and translocation 
(“flipping”) of the positively charged lysyl-phosphatidylglycerol (L-PG) from the 
inner to the outer leaflet of the CM (317).  Moreover, it has been shown that L-
PG attenuates membrane perturbations caused by cationic antimicrobial peptides 
(332).  Our findings suggest that, similar to S. aureus, development of DAP-
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resistance in vancomycin-resistant E. faecalis is also associated with increased 
cell surface charge.  However, unlike S. aureus, enterococci possess other amino-
containing PL apart from L-PG including arginyl-, alanyl-, and diglucosyl-PG 
(333) which could also alter the CM charge or stabilize the CM and, thus, may 
contribute to the DAP-resistance phenotype.    
Taken together, we have shown that the emergence of DAP resistance 
during therapy of VRE is associated with important alterations in DAP-induced 
CM potential and permeabilization with an increase in net cell surface charge. In 
addition, alterations of CM similar to those observed in S. aureus appear to play 
a role in DAP resistance in VRE. Our results suggest that the development of in 
vivo DAP resistance in VRE is associated with marked structural changes in the 
cell envelope with alterations in cell division and increased CW thickness.  
Notably, the genetic strategy used by enterococci appears to be different from 
that described in S. aureus (personal communication, Cesar A. Arias, MD, PhD, 
University of Texas Medical School). Indeed, none of the genes previously 
associated with the emergence of DAP-resistance in S. aureus (319, 251) 
appeared mutated in the DAP-resistant isolate compared to its DAP-susceptible 
parental strain. Recent findings (unpublished, personal communication, Cesar A. 
Arias, MD, PhD, University of Texas Medical School) provide compelling 
evidence that changes in genes encoding CM phospholipid synthesis enzymes, 
namely CL synthase and glycerophosphoryl diesterphosphodiesterase in E. 
faecalis are important for development of DAP-resistance in enterococci.  
Findings (unpublished, personal communication, Cesar A. Arias, MD, PhD, 
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University of Texas Medical School) derived from genomic analysis of E. 
faecalis also identified unique mutations in the genes encoding a three 
component-regulatory system (LiaFRS, for lipid-II interacting antibiotics), not 
previously associated with DAP-resistance in S. aureus. This unique system is 
known to orchestrate the cell envelope response to antibiotics and antimicrobial 
peptides in some Gram-positive bacteria (the genes are present in most 
Firmicutes). The LiaFSR system has been well characterized in B. subtilis (334) 
Streptocococus mutans and pneumococci (335). In B. subtilis and S. mutans, the 
LiaFSR system is usually activated by the presence of antibiotics that disrupt CM 
(i.e., bacitracin, daptomycin, ramoplanin, nisin and vancomycin (334).   In B. 
subtilis, LiaF is a membrane-anchored, negative regulator of LiaS (which is the 
sensor protein of the system and also functions as a histidine kinase that 
phosphorylates the response regulator, LiaR). LiaF interferes with the histidine 
kinase autophosphorylation by direct interactions, thereby suppressing activation 
of the cognate response regulator (LiaR) (336).  Additionally, it is important to 
note that there may be several pathways for the development of DAP-resistance 
in enterococci, as shown in S. aureus (251, 337).   
Taken together, we have shown that a synthetic AMP able to disrupt 
bacterial membrane non-specifically is active against Gram-negative organisms 
such as P. aeruginosa, K. pneumoniae, E. coli and A. baumannii, regardless of 
their antibiotic resistance profiles. We speculate that targeting the cell outer layer 
may represent a new strategy for antimicrobial development since the CM is 
essential for microbe integrity as well as energy storage. Although the scientific 
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community does not see development of resistance to AMPs as a concern, 
reduced sensitivity of S. aureus and E. faecalis to de-novo AMP, DAP, emerged 
as a result of treatment.  Resistance associated with DAP include, most 
importantly, modifications to the thick peptidoglycan layer surrounding the CM 
of Gram-positive organisms. Since this is a Gram-positive specific cell feature, 
the mechanism of resistance related to changes in the peptidoglycan layer is also 
specific to Gram-positive cells.   
In summary, the detailed analysis of the mode of action of the AMP 
D(KLAKLAK)2  with lipid bilayers may represent a stepping-stone for the 
development or improvement of drugs with broad activity against in Gram-
negative bacterial membrane.  We also believe that type of DAP resistance 
acquired by enterococci and staphylococci will not affect the treatment with 
D(KLAKLAK)2 because resistance to DAP in these organisms is related to Gram-
positive specific cell features such as the cell-wall. 
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